| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Perrigo Company plc$10.22
-0.19 (-1.83%)
C 51Pipeline Score Undervalued Generics · Commercial
Market Cap
1.55 B
EPS
-13.10
P/E Ratio
-
Value Trade
24.27 M
SEC Financials
Q1 2026Dilution Risk
Revenue
969.20 M
R&D Expenses
24.60 M
Operating CF
-113.60 M
Total Assets
7.98 B
Total Liabilities
5.48 B
Equity
2.50 B
D/E Ratio
12,345
4.66 %
Week
-5.08 %
1 Month
-24.7 %
3 Month
-8.63 %
6 Month
-75.23 %
5 Year
-51.22 %
All Time
Cash Data
Cash Position
357.20 M
Monthly Burn
37.87 M
Runway
7.5 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
3.39 M
52 Week Range
9.23 - 28.44
% held by Insiders
0.43 %
% held by Institutions
113.38 %
Enterprise Value
5.00 B
Total Shares
138.42 M
Short %
17.84 %
Float Shares
137.73 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Perrigo Company plc
550Total events
1Upcoming
132Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 1
2028
T2Timing Guidance
Supply Chain Reinvention Program annualized run-rate savings target by end of 2028
Event history 549
Jun 9, 2026
◆Oral PresentationPresentation
Perrigo to present at Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
Jun 8, 2026
◆Management ChangeCorporate
Patrick Lockwood-Taylor resigns as President and CEO and Board member
May 6, 2026
Apr 30, 2026
Mar 11, 2026
◆Oral PresentationPresentation
Perrigo to present at UBS Global Consumer and Retail Conference
Feb 26, 2026
Feb 26, 2026
▲Restructuring LayoffsCorporate
Launching new operational enhancement program with $80-100M annualized savings
Q1 2026
◆AcquisitionCorporate
Sale of Dermacosmetics business on track to close in Q1 2026
Dermacosmeticssource ↗
Drug Pipeline Intelligence
C51
Pipeline Score $2.2B
Pipeline ValueUndervalued
Valuation Signal8
Drugs Scored4.7x
rNPV / MCap Top 77%
Micro Cap (rank 211 of 911)
Percentile RankPerrigo Company plc carries a moderate pipeline score (51/100), with $7.3B risk-adjusted pipeline value, led by Norgestrel in Contraception (Phase 3), across $85B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norgestrel Small molecule | Contraception | Phase 3 | NCT03585712 | 55% | $1.7B | COMPLETED | 1,014 | - | - | Apr 7, 2020 | - | Jun 3, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRGO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRGO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRGOPerrigo Announces Appointment of Two New Independent Directors to Board
Perrigo Company plc has appointed Salman Amin and Omer Gajial as independent directors, effective June 30, 2026. Both directors bring extensive experience in consumer products and retail, which is expected to support Perrigo's strategic priorities. The appointments are seen as a positive step towards enhancing the company's operational excellence and growth.
Read more →PRGO▲ +7.2%on this news
Perrigo Announces Leadership Transition Albert A. Manzone Appointed Interim President and CEO Patrick Lockwood-Taylor Resigns as President and CEO and as a Member of the Board DUBLIN
Perrigo Company plc has appointed Albert A. Manzone as Interim President and Chief Executive Officer following the resignation of Patrick Lockwood-Taylor due to personal conduct issues. The Board has initiated a search for a permanent successor while expressing confidence in Manzone's leadership capabilities, given his extensive experience and familiarity with the company. Despite the leadership change, Perrigo has reaffirmed its financial outlook for 2026 and aims to maintain its strategic direction during this transition.
Read more →PRGO▲ +7.2%on this news
Perrigo Announces Leadership Transition
Perrigo Company plc has appointed Albert A. Manzone as Interim President and CEO following the resignation of Patrick Lockwood-Taylor due to personal conduct issues. The Board is conducting a search for a permanent successor. Manzone aims to maintain continuity and support the leadership team while reaffirming the company's financial outlook for 2026.
Read more →PRGOPerrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
Perrigo Company plc announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on June 9th. The presentation will be accessible via webcast on Perrigo's website. The company is recognized for its extensive experience in consumer health products.
Read more →PRGO▲ +5.3%on this news
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
Perrigo Company plc reported its first quarter 2026 financial results, showing a commitment to transforming its business despite a challenging environment. The company is focused on a category-led operating model and has reaffirmed its full-year guidance, supported by growth in specific segments like Women's Health. However, net sales have declined significantly, and operating income in the Self Care segment has decreased sharply.
Read more →PRGOPerrigo Completes Divestiture of Dermacosmetics Business Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading global provider of consumer health products, today announced that it has...
Perrigo Company plc has completed the divestiture of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, which includes €305.6 million in upfront cash. This move is part of Perrigo's Three-S strategy aimed at stabilizing, streamlining, and strengthening the company. The proceeds from this transaction are intended primarily for debt reduction, thereby improving financial flexibility. The Dermacosmetics business had generated approximately €120 million in net sales in 2025, representing about 5% of Perrigo's adjusted operating income.
Read more →PRGOPERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES SELECT CONSOLIDATED INFORMATION QUARTERS AND CALENDAR YEAR TO DATE 2025 (in millions) (unaudited) Three Months Ended Twelve Months Ended Consolidated Continuing Ope
Perrigo Company PLC provided detailed information regarding its consolidated financials and non-GAAP measures for the fiscal year and quarters ended in 2025. The report indicated strong sales in the Self Care segment, totaling $2,533.5 million for the year, while total adjusted operating income reached $682.6 million. However, the company also reported a substantial goodwill impairment charge of $1.3 billion in the fourth quarter and a significant operating loss of $1,287.2 million for the same period, highlighting financial challenges in specific areas of its operations.
Read more →PRGOPerrigo to Release First Quarter 2026 Financial Results on May 6, 2026
Perrigo Company plc has announced that it will release its first quarter 2026 financial results on May 6, 2026. The company will host a conference call at 8:30 A.M. (EST) to discuss these results, which will be accessible via webcast or phone. A replay of the call will be available for a week following the event.
Read more →PRGOPerrigo to Present at the UBS Global Consumer and Retail Conference
Perrigo Company plc announced that its President and CEO, Patrick Lockwood-Taylor, will present at the UBS Global Consumer and Retail Conference on March 11th. The presentation will be accessible via a webcast on the company's investor relations website. Perrigo is recognized for its extensive experience in consumer health solutions, particularly in the OTC market.
Read more →PRGOPerrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations
Perrigo Company plc reported its financial results for the fourth quarter and fiscal year 2025, highlighting a decline in net sales and a significant goodwill impairment charge. Despite these challenges, the company gained market share in store brands and launched an operational enhancement program aimed at generating substantial cost savings. Looking ahead, Perrigo has outlined its fiscal year 2026 outlook, which reflects ongoing market pressures but also opportunities for growth.
Read more →PRGOPerrigo Announces Quarterly Dividend Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a...
Perrigo Company plc announced the approval of a quarterly dividend of $0.29 per share, which translates to an annualized rate of $1.16. This dividend is set to be paid on March 24, 2026, to shareholders who are on record by March 2, 2026. The company emphasizes its role as a leading provider of consumer health solutions, leveraging its business model to support brand investments while providing accessible OTC self-care products.
Read more →PRGOPerrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
Perrigo Company plc announced it will release its fourth quarter and fiscal year 2025 financial results on February 26, 2026. The company will host a conference call at 8:30 A.M. (EST) to discuss these results, which will be accessible via webcast and phone. A replay of the call will be available shortly after the event.
Read more →PRGOPERRIGO FINAL CLASS ACTION DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Perrigo Company plc Investors of the Upcoming January 16th Deadline and Urges Investors to Contact the Firm
Perrigo Company plc is facing a class action lawsuit for failing to disclose key issues with its infant formula business, including underinvestment and manufacturing deficiencies. The lawsuit covers transactions from February 27, 2023, to November 4, 2025, with a deadline for investors to apply as lead plaintiffs by January 16, 2026. The company revealed significant financial shortcomings and re-evaluated its strategic investments in this sector, leading to a notable decline in stock price. Investors are encouraged to contact the law firm Bragar Eagel & Squire for further information on their rights.
Read more →PRGOPERRIGO (PRGO) CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Perrigo Company plc Investors of the Upcoming January 16th Deadline and Urges Investors to Contact the Firm
A class action lawsuit has been filed against Perrigo Company plc for failing to disclose critical issues regarding its infant formula business. Investors who acquired Perrigo securities between February 27, 2023, and November 4, 2025, are encouraged to participate in the case, which alleges significant operational deficiencies and overstated financial results. Following the company's disappointing third-quarter results announced on November 5, 2025, Perrigo's stock price dropped by over 25%. The firm has announced a strategic review of its infant formula business amid concerns over significant operational expenditures.
Read more →PRGOPERRIGO COMPANY PLC (NYSE: PRGO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Perrigo Company plc Investors of Upcoming Deadline
Perrigo Company plc is under scrutiny as Bernstein Liebhard LLP announces a class action lawsuit for securities fraud. The lawsuit, filed in the Southern District of New York, alleges misrepresentation related to the company's acquisition of an infant formula business from Nestlé. Investors who purchased shares between February 27, 2023, and November 4, 2025, are reminded of the approaching deadline to participate in the class action. They are urged to file by January 16, 2026, if they wish to serve as lead plaintiffs.
Read more →PRGOPerrigo Company plc Sued for Securities Law Violations - Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights – PRGO
Perrigo Company plc is currently embroiled in a securities lawsuit stemming from allegations of issuing misleading statements and failing to disclose operational deficiencies within its infant formula business. The class action period spans from February 27, 2023, to November 4, 2025, and claims that the company overstated its financial results. The Gross Law Firm is actively encouraging affected shareholders to participate in the class action, with a lead plaintiff application deadline set for January 16, 2026. The firm asserts that significant capital expenditures will be necessary to address the alleged manufacturing and operational issues.
Read more →PRGOPERRIGO CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Encourages Perrigo Company plc Investors to Contact the Firm Before January 16th Regarding Their Rights
Bragar Eagel & Squire, P.C. announced a class action lawsuit against Perrigo Company plc for alleged disclosures failures regarding its infant formula business from February 2023 to November 2025. The lawsuit claims that Perrigo did not reveal significant underinvestment and manufacturing deficiencies in this segment, affecting its financial performance. Following a disappointing earnings report, Perrigo's stock price dropped 25.2%, prompting a strategic review of its infant formula business. Investors are encouraged to contact the firm by January 16, 2026, to explore their legal options.
Read more →PRGOPerrigo Company plc Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights – PRGO
Perrigo Company plc is facing a class action securities lawsuit filed by Levi & Korsinsky, LLP on behalf of investors who experienced losses between February 2023 and November 2025. The lawsuit alleges that the company made misleading statements about its financial health and operations, particularly concerning its acquired infant formula business from Nestlé. Specific claims include underinvestment in maintenance and significant manufacturing deficiencies, which purportedly inflated financial results. Investors are encouraged to contact the law firm to discuss their rights and potential compensation.
Read more →PRGOPERRIGO COMPANY PLC (NYSE: PRGO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Perrigo Company plc Investors of Upcoming Deadline
Bernstein Liebhard LLP has alerted investors of Perrigo Company plc about a pending deadline related to a securities fraud class action lawsuit. This lawsuit alleges that the company made false statements regarding its infant formula business acquired from Nestlé. Investors who purchased Perrigo shares between February 27, 2023, and November 4, 2025, may need to consider their legal options. The deadline to file as a lead plaintiff is January 16, 2026.
Read more →PRGOPerrigo Company plc Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights – PRGO
Perrigo Company plc is facing a securities fraud class action lawsuit, with allegations stemming from a class period between February 27, 2023, and November 4, 2025. The lawsuit claims that the company issued misleading statements regarding its infant formula business, suggesting that it had significant operational and capital issues that were not disclosed to investors. Shareholders who purchased shares during this period are encouraged to register with The Gross Law Firm before the January 16, 2026 deadline. The firm is set to monitor the case and assist those who have incurred losses due to the alleged misrepresentations.
Read more →PRGOPerrigo Company plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – PRGO
Perrigo Company plc is currently involved in a class action lawsuit for violating securities laws, specifically related to its acquisition of Nestlé's baby formula business. The case alleges that Perrigo made false and misleading statements concerning the unit's financial health, which suffered from significant underinvestment. As a result, shareholders who acquired shares during the specified class period are encouraged to register for potential recovery of losses. The deadline for participation in this lawsuit is January 16, 2026.
Read more →PRGOPerrigo Company plc Class Action: Levi & Korsinsky Reminds Perrigo Company plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 – PRGO
Perrigo Company plc is currently facing a class action securities lawsuit, with a focal point on alleged fraud that occurred between February 27, 2023 and November 4, 2025. The lawsuit claims that the company's management made false statements regarding their infant formula business, indicating significant operational deficiencies and overstated financial results. Investors who experienced losses during this period are encouraged to consider participating in the lawsuit, with a deadline for lead plaintiff applications set for January 16, 2026. Legal representation is offered at no cost to class members.
Read more →PRGOPerrigo to Attend Morgan Stanley Global Consumer & Retail Conference
Perrigo Company plc announced its participation in the Morgan Stanley Global Consumer & Retail Conference, scheduled for December 2, 2025. President and CEO Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will engage in one-on-one investor meetings. This event underscores Perrigo's commitment to investor relations and its position in the consumer health market.
Read more →PRGOPERRIGO COMPANY PLC (NYSE: PRGO) INVESTOR ALERT Investors With Large Losses in Perrigo Company plc Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A securities class action lawsuit has been filed against Perrigo Company plc, initiated by a shareholder on behalf of investors who acquired its securities between February 27, 2023, and November 4, 2025. The lawsuit claims that Perrigo made misrepresentations regarding its infant formula business acquired from Nestlé. Investors interested in leading the lawsuit must act by January 16, 2026, while the legal representation operates on a contingency fee basis, implying no upfront costs for plaintiffs.
Read more →PRGO▼ -25.2%on this news
Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations
Perrigo Company plc reported its financial results for the third quarter of 2025, highlighting gains in market share across several over-the-counter categories despite facing soft consumption trends. The company has adjusted its full-year outlook primarily due to challenges in the infant formula market. CEO Patrick Lockwood-Taylor emphasized the strength of their strategic initiatives, which have led to year-to-date earnings growth.
Read more →PRGO▼ -25.2%on this newsshared move
Perrigo to Conduct Strategic Review of its Infant Formula Business
Perrigo Company plc has announced a strategic review of its infant formula business to explore various alternatives. This initiative aligns with its 'Three-S' plan aimed at optimizing capital allocation and enhancing shareholder returns. The review will consider the company's $240 million investment in the business, which is expected to generate significant sales but represents a small portion of overall revenue. The outcome of the review remains uncertain, with no specific timeline provided.
Read more →PRGOPerrigo to Attend Jefferies Consumer Conference
Perrigo Company plc will participate in one-on-one investor meetings at the Jefferies Miami Consumer Conference on November 18, 2025. President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will represent the company. Perrigo is recognized for its extensive experience in consumer health products, particularly in the OTC self-care market.
Read more →PRGOPerrigo Announces Quarterly Dividend
Perrigo Company plc announced a quarterly dividend of $0.290 per share, which will be paid on December 16, 2025, to shareholders on record as of November 28, 2025. The company continues to leverage its strong position in the consumer health market, focusing on accessible self-care solutions. This announcement reflects Perrigo's commitment to returning value to its shareholders.
Read more →PRGOPerrigo to Release Third Quarter 2025 Financial Results on November 5, 2025
Perrigo Company plc has announced the release date for its third quarter 2025 financial results, which will be available on November 5, 2025. The company will host a conference call at 8:30 A.M. (EST) to discuss these results, accessible via webcast and phone. A replay of the call will be available for a limited time after the event.
Read more →PRGOOpill® Nails It with First-Ever Brand Collaboration, Launching 'Opill and Chill' With Chillhouse
Perrigo Company has partnered with Chillhouse to launch 'Opill and Chill', promoting self-care and reproductive health. For each set of themed press-on nails sold, a pack of Opill will be donated to the NY Birth Control Access Project. The initiative aims to empower women and challenge outdated norms surrounding wellness.
Read more →PRGOPerrigo to Attend Barclays 18th Annual Global Consumer Staples Conference
Perrigo Company plc announced its participation in one-on-one investor meetings at the Barclays 18th Annual Global Consumer Staples Conference on September 3rd, 2025. President Patrick Lockwood-Taylor and CFO Eduardo Bezerra will represent the company. Perrigo is known for its self-care products and has a strong presence in North America and Europe.
Read more →PRGO▼ -11.3%on this news
Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations Company Advanced its Three-S' Plan (Stabilize, Streamline, and Strengthen) with Recently Announced Agreement to Sell Dermacosmetics Busines
Perrigo Company plc announced its financial results for the second quarter of 2025, revealing a 0.9% decline in net sales year-over-year. Despite this decrease, the company showcased an improved operating income, moving from a loss in the previous year to $45 million. The firm reaffirmed its earnings outlook for the year while highlighting ongoing challenges, particularly in its infant formula segment. Additionally, Perrigo plans to sell its Dermacosmetics business, a strategic move aimed at reinforcing its organizational focus and financial health.
Read more →PRGOPerrigo Announces Quarterly Dividend Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a...
Perrigo Company plc has announced the declaration of a quarterly dividend of $0.290 per share, which is payable to shareholders on September 16, 2025. Shareholders of record as of August 29, 2025, will receive this dividend. The company is recognized as a leader in the consumer self-care market, providing a range of health and wellness solutions, primarily in North America and Europe. Perrigo's business model supports a mix of private label offerings and well-known brands, ensuring accessibility to a variety of self-care products.
Read more →PRGOPerrigo to Present at the Canaccord Genuity 45th Annual Growth Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor...
Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Patrick Lockwood-Taylor, and CFO, Eduardo Bezerra, will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The presentation is expected to include forward-looking statements regarding the company's performance and market position. Interested stakeholders can access the webcast via Perrigo's investor relations website. The company emphasizes its commitment to high-quality self-care solutions in North America and Europe.
Read more →PRGOPerrigo to Release Second Quarter 2025 Financial Results on August 6, 2025 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2025...
Perrigo Company plc plans to release its second quarter 2025 financial results on August 6, 2025. Alongside the release, a conference call will be held at 8:30 A.M. (EST) to discuss the results, which will be accessible via webcast and phone. The call will also be available for replay shortly after the event. Perrigo continues to establish itself as a leading provider in the consumer self-care sector, utilizing a business model that supports both private label and branded products.
Read more →PRGOPerrigo Announces Agreement to Divest Dermacosmetics Business for up to €327 Million Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading global provider of Consumer Self-Care Products, today announced it has...
Perrigo Company plc announced the sale of its Dermacosmetics business to Kairos Bidco AB, managed by KKR, for up to €327 million. This includes €300 million in upfront cash, with potential future payments tied to net sales milestones. The proceeds will assist in strengthening Perrigo's balance sheet as part of its 'Three-S' plan aimed at streamlining operations. The transaction is expected to close in early 2026, pending regulatory approval and other conditions.
Read more →PRGOPerrigo Announces Proposed Divestiture of Dermacosmetics Business for up to 327 Million Proposed Divestiture Advances Company s Three-S Plan to Streamline its Portfolio and Strengthen Focus on its High-Grow Brands Total
Perrigo has announced the proposed divestiture of its Dermacosmetics business to Kairos Bidco AB for a total consideration of up to $327 million. This includes $300 million in upfront cash and up to $27 million based on future sales milestones. The move is part of Perrigo's strategic Three-S plan to stabilize, streamline, and strengthen its focus on high-growth brands. Closing of the transaction is anticipated in the first quarter of 2026, pending customary approvals.
Read more →PRGOPerrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance Company to Scale and Optimize Global Category-Led, Market Activation Growth Model Roberto Khoury, EVP & President Consumer Sel
Perrigo Company plc announced a strategic organizational update to enhance growth and performance through a global category-led, market activation approach. This restructuring involves the appointment of Roberto Khoury as EVP and Chief Commercial Officer and the departure of Triona Schmelter. The alignment aims to improve agility and deeper engagement with customers while supporting Perrigo's ongoing growth efforts. Implementing this plan will follow legal information and consultation processes and is expected to unfold in the coming months.
Read more →PRGOPerrigo Announces Global Operations and Supply Chain Leadership Transition Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy
Perrigo Company has announced the retirement of Ron Janish, EVP of Global Operations and Supply Chain, effective September 30, 2025. Matt Winterman has been appointed as his successor and will take on the role of EVP Product Supply, Operations Strategy and Transformation Officer. The leadership transition aims to ensure continuity in Perrigo's operations and supply chain strategies, building upon Janish's significant contributions over two decades, particularly during the COVID-19 pandemic. Winterman's extensive background in supply chain management from companies like AstraZeneca and Roche is expected to enhance Perrigo's operational excellence in self-care solutions.
Read more →PRGOPerrigo to Attend the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor...
Perrigo Company plc, a significant player in the Consumer Self-Care Products sector, announced its participation in the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference on June 10. The presentation will feature insights from President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra. Perrigo's focus on accessible over-the-counter self-care solutions highlights its commitment to consumer health and wellness, leveraging its unique business model for growth. Interested parties can access the presentation via webcast.
Read more →PRGO▲ +7%on this news
Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong
Perrigo Company reported its first quarter 2025 financial results, showing a 3.5% decline in net sales primarily due to divestitures and currency impacts, despite strong adjusted EPS growth of 106.9%. The company pointed out ongoing challenges from macroeconomic uncertainties, leading to a revision of its sales growth targets. However, stabilization efforts in the infant formula business resulted in notable organic growth in the Nutrition category. Nevertheless, distribution losses in lower margin products and the absence of prior year benefits impacted overall performance.
Read more →PRGOPerrigo to Release First Quarter 2025 Financial Results on May 7, 2025 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025...
Perrigo Company plc announced plans to release its financial results for the first quarter of 2025 on May 7. The company will host a conference call at 8:30 A.M. (EST) to discuss the results, which can be accessed via webcast or phone. A replay of the call will be available later in the day. This announcement indicates Perrigo's commitment to transparency and communication with its investors.
Read more →PRGO▲ +20.2%on this news
Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that at its Virtual Investor Day, scheduled to...
Perrigo Company plc has outlined its strategic plan during its Virtual Investor Day, focusing on consumerizing, simplifying, and scaling its global self-care platform. The management emphasized a 'Three-S' strategy aimed at stabilizing their consumer self-care business, streamlining operations, and strengthening their high-growth brands. With optimistic projections for earnings growth and cash flow, Perrigo aims to enhance shareholder returns through a focus on innovative products and partnerships. The company also provided financial targets for fiscal years 2025 to 2027, while acknowledging potential risks related to market conditions and operational challenges.
Read more →PRGOPerrigo Reports Fourth Quarter Fiscal Year 2024 Financial Results From Continuing Operations Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value A
Perrigo Company plc reported its fourth quarter and fiscal year 2024 financial results, highlighting adjusted EPS of $2.57 and a notable 17% growth in infant formula net sales compared to the prior year. Despite overall net sales declining by 1.6% due to divestures and unfavorable currency translation, the company achieved improved operating margin levels. The recent FDA inspection yielded no significant negative findings, allowing the company to stabilize its infant formula operations. Management is set to present a strategic plan for 2025-2027 at an upcoming Investor Day event.
Read more →PRGOPerrigo to Attend the UBS 2025 Global Consumer and Retail Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor...
Perrigo Company plc (NYSE: PRGO) announces its participation in the UBS 2025 Global Consumer and Retail Conference, scheduled for March 12, 2025. The company will be represented by President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra. Interested parties can access a live webcast of the presentation via the Perrigo website. This event showcases Perrigo's focus on consumer self-care products and its efforts to engage with investors and stakeholders.
Read more →PRGOPerrigo Increases Quarterly Dividend by 5% Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors has approved...
Perrigo Company plc has announced a 5% increase in its quarterly dividend, bringing it to $0.290 per share, or $1.16 annually. This marks the company's 22nd consecutive year of raising its dividend, demonstrating its commitment to returning value to shareholders. The dividend payment is scheduled for March 25, 2025, to shareholders on record as of March 7, 2025. The announcement highlights Perrigo's ongoing financial stability in the consumer self-care sector.
Read more →PRGOOpill® extends mission of breaking down birth control barriers with launch of multi-state college tour and expansion of partnerships Today, Opill®— the first and only daily birth control pill available without a prescription in the U.S. —launched an educational college campus tour...
Opill, the first over-the-counter birth control pill in the U.S., has initiated a multi-state campus tour to promote reproductive health education. The program, in partnership with the WNBA and the Black Women's Health Imperative, focuses on expanding access to birth control resources, particularly in states with restrictive reproductive health laws. Events will engage students at various colleges and universities, emphasizing the importance of understanding contraception options. Additionally, the initiative includes the establishment of the BWHI Opill Access Fund to support Black women facing barriers to obtaining birth control.
Read more →PRGOPerrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and...
Perrigo Company plc has announced it will release its fourth quarter and fiscal year 2024 financial results on February 27, 2025, following the close of U.S. equity markets. Additionally, the company will host a Virtual Investor Day on February 28, 2025, aimed at engaging with investors. Interested attendees can access the event online and are encouraged to register in advance. The announcement highlights Perrigo's commitment to transparency and investor relations.
Read more →PRGOPerrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific...
Perrigo Company has announced the expansion of its Chief Scientific Office by integrating all global quality, regulatory affairs, and innovation teams. This structural change is intended to enhance the company's agility and support its consumer-led innovation pipeline. Abbie Lennox has been appointed as the Executive Vice President and Chief Scientific Officer, bringing extensive experience from her previous role at Bayer. Additionally, Alison Ives, the former Chief Scientific Officer, will lead a newly formed Disruptive Growth Team focusing on emerging market opportunities.
Read more →PRGO▲ +7.7%on this news
Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations Company Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion Infant Formula Bu
Perrigo Company plc (NYSE PRGO) announced its third quarter 2024 financial results, revealing a solid performance despite some challenges. Net sales reached $1.1 billion, down 3.2% year-over-year, while the company reported adjusted diluted EPS of $0.81, up 26.6% from the prior year. Significant gains were observed in the infant formula market, with a 3% net sales growth year-over-year and a remarkable 58% increase sequentially. The company reaffirmed its adjusted EPS outlook for fiscal 2024, but noted a decrease in overall net sales, primarily due to lost distribution of lower margin products.
Read more →PRGOPerrigo to Release Third Quarter 2024 Financial Results on November 6, 2024 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2024...
Perrigo Company plc (NYSE: PRGO) has announced its plans to release third quarter financial results on November 6, 2024. The company will host a conference call at 8:30 A.M. (EST) that will be accessible to interested parties via webcast and phone. A taped replay will be available shortly after the call until November 13, 2024. This upcoming earnings release will incorporate forward-looking statements, highlighting potential risks and uncertainties.
Read more →PRGOWNBA Star Napheesa Collier Joins Team Opill® for Candid Conversations on Women's Health Today, Opill®—the first and only daily birth control pill available without a prescription in the U.S.—announces the launch of its partnership with...
Perrigo's Opill® has partnered with WNBA star Napheesa Collier to promote women's reproductive health awareness. Collier, a two-time Olympic Gold Medalist, aims to address crucial conversations about birth control options and empower women with knowledge. This initiative focuses on reaching college students to enhance understanding of Opill® and its availability as a prescription-free contraceptive. Collier's involvement is also seen as a way to improve access to reproductive health for future generations.
Read more →PRGOPerrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced a new brand partnership: Good Start®1 and ...
Perrigo Company plc announced a new partnership with Dr. Brown's to launch the Good Start® | Dr. Brown's™ infant formula portfolio. This initiative combines two trusted brands to provide families with nutritionally optimized infant formula solutions aimed at addressing common formula tolerance issues. The products will feature refreshed packaging and will be available at major retailers, including Walmart and Amazon. The partnership exemplifies Perrigo's strategy of consumer-led innovation in the self-care sector.
Read more →PRGOPERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY Dublin, Ireland
Perrigo Company plc announced the successful closing of a senior notes offering through its finance subsidiary, Perrigo Finance Unlimited Company. The offering raised $715 million in USD and €350 million in Euro, intended for debt redemption and prepayment of loans. The total net proceeds are estimated at approximately $1,076 million after expenses. This move is part of Perrigo's strategy to strengthen its financial position and manage its credit facilities more effectively.
Read more →PRGOPERRIGO ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY Perrigo Company plc ( Perrigo or the Company ) (NYSE: PRGO) today announced the pricing of a registered public offering by Perrigo Finance...
Perrigo Company plc has announced the successful pricing of a registered public offering by its subsidiary, Perrigo Finance Unlimited Company. The offering includes $715 million of 6.125% Senior Notes and €350 million of 5.375% Senior Notes, both due in 2032. The funds generated from this offering will be aimed at redeeming existing senior notes and prepaying a portion of Term B Loans. Closing of the offering is expected around September 17, 2024, pending certain conditions.
Read more →PRGOPerrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as...
Perrigo Company plc (NYSE: PRGO) has appointed Charles Atkinson as its new Executive Vice President, General Counsel, and Secretary. Atkinson, who has nearly 25 years of experience in the regulated consumer self-care industry, previously held a key legal role at Haleon plc. President and CEO Patrick Lockwood-Taylor praised Atkinson's skills, emphasizing his expertise in global regulatory matters and intellectual property. The transition follows Todd Kingma's temporary leadership in the role, ensuring continuity in Perrigo's legal guidance.
Read more →PRGOPerrigo to Attend the Piper Sandler Growth Frontiers Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor...
Perrigo Company plc (NYSE: PRGO) has announced its participation in the Piper Sandler Growth Frontiers Conference, scheduled for September 10, 2024. President and CEO Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will present at the event. Interested parties will be able to access the live webcast on Perrigo's website. The company, known for its consumer self-care products, continues to prioritize engagement with investors and stakeholders.
Read more →PRGOPerrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as...
Perrigo Company plc has appointed Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer, a newly created role aimed at enhancing the company's marketing strategies. Dr. Ball, who has over 15 years of global experience in consumer goods including leadership roles at Bayer and Procter & Gamble, will focus on developing brand strategies and identifying market opportunities. The company views his expertise as crucial in strengthening its position in the over-the-counter health market.
Read more →PRGOPerrigo Reports Second Quarter 2024 Financial Results From Continuing Operations Delivered Adjusted Diluted Earnings Per Share Results as Expected Reaffirm Fiscal 2024 Adjusted Diluted EPS Outlook Progressing One Perrigo
Perrigo Company plc reported its financial results for the second quarter of 2024, witnessing a net sales decline of 10.7% year-over-year, attributed primarily to lower infant formula sales and reduced seasonal demand in certain product categories. Despite these challenges, the company confirmed its adjusted diluted EPS forecast for fiscal 2024 but adjusted its organic net sales growth outlook from a previously positive projection to a range of -3% to -1%. The CEO expressed confidence in ongoing recovery efforts and projected improvements in the second half of the year, specifically in the infant formula business.
Read more →PRGOPerrigo to Attend the Canaccord Genuity 44th Annual Growth Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor...
Perrigo Company plc (NYSE: PRGO) has announced its participation in the Canaccord Genuity 44th Annual Growth Conference, scheduled for August 14, 2024. The presentation will feature President and CEO Patrick Lockwood-Taylor, alongside CFO Eduardo Bezerra. This participation highlights Perrigo's role as a significant provider of consumer self-care products and their commitment to engaging with investors and stakeholders. Interested parties can access the webcast via Perrigo's official website.
Read more →PRGOPerrigo to Release Second Quarter 2024 Financial Results on August 2, 2024 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2024...
Perrigo Company plc has announced its plan to release the financial results for the second quarter of 2024 on August 2, 2024. The Company will host a conference call at 8:30 A.M. (EST) to discuss these results, which can be accessed via webcast or phone. A replay of the call will be available for a week following the event. This information emphasizes Perrigo's ongoing commitment to transparency and engagement with its investors.
Read more →PRGOPerrigo Completes Divestment of HRA Pharma Rare Diseases Business Dublin, Ireland
Perrigo Company plc has finalized the divestment of its HRA Pharma Rare Diseases business to Esteve Healthcare for a total of up to 275 million. This includes an upfront cash payment of 190 million and potential future earnouts based on sales performance. The company plans to use the proceeds for debt repayment, anticipating improved financial stability. The impact of this transaction was previously incorporated into Perrigo's 2024 financial outlook.
Read more →PRGOPerrigo to Attend Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor...
Perrigo Company plc (NYSE: PRGO) has announced that its President and CEO Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will present at the Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference. The event is scheduled to be held virtually on June 11, 2024. Interested parties can access the webcast through the Perrigo website. The announcement emphasizes the company's position in the consumer self-care products sector.
Read more →PRGO▼ -9.8%on this news
Perrigo Announces Executive Transition for its Consumer Self-Care International (CSCI) Business Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Svend Andersen, Executive Vice President...
Perrigo Company plc has announced the retirement of Svend Andersen, Executive Vice President and President of its Consumer Self-Care International (CSCI) segment, by December 2024. Roberto Khoury, a veteran in the consumer health space, will take over the leadership role in August 2024. Andersen will assist in the transition until then and has been credited with significant contributions to the division's growth. This change is expected to bring fresh perspectives and innovation to Perrigo's self-care product offerings.
Read more →PRGO▼ -9.8%on this news
Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments Reaffirm 2024 Fi
Perrigo Company plc reported its first quarter 2024 financial results, revealing a net sales decline of 8.4% year-over-year, primarily impacted by issues within the infant formula segment. Despite these challenges, the company achieved adjusted diluted earnings per share above projections and successfully launched the Opill birth control pill. The firm reaffirms its 2024 financial outlook, aiming for modest organic net sales growth. Operational restructuring initiatives are underway, aiming for significant cost savings through Project Energize, while leadership transitions within the company are also planned.
Read more →PRGOPerrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase...
Perrigo Company has announced a binding offer from Esteve Healthcare to acquire its HRA Pharma Rare Diseases business for up to €275 million. The offer consists of €190 million in upfront cash, with an additional €85 million tied to performance milestones. This divestment supports Perrigo's strategic shift towards consumer self-care products and aims to lower the company's net leverage below 4.0x by the end of 2024. The transaction is expected to close in Q3 2024, pending regulatory approval and consultation processes.
Read more →PRGOPerrigo to Release First Quarter 2024 Financial Results on May 7, 2024 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024...
Perrigo Company plc has announced the release date for its financial results for the first quarter of 2024, scheduled for May 7, 2024. The company will hold a conference call at 8:30 A.M. (EDT) to discuss these results, which will be accessible via a live webcast and telephone. This initiative demonstrates Perrigo's ongoing commitment to transparency and investor engagement in the consumer self-care products sector.
Read more →PRGOOpill and WNBA Team Up for Groundbreaking Partnership Today, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that Opill® — the first-ever daily birth control pill...
Perrigo Company plc has announced a multi-year partnership with the Women's National Basketball Association (WNBA) to promote Opill®, the first-ever daily birth control pill available without a prescription in the U.S. The collaboration aims to enhance women's reproductive health education and access through various initiatives. Opill® will debut as an Associate Partner during the upcoming 2024 WNBA Draft. This partnership underscores a shared commitment between both organizations to advocate for health equity and civic engagement, particularly in communities of color.
Read more →PRGOPerrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Opill® has shipped to major retailers and...
Perrigo Company plc has announced the nationwide shipment of Opill®, the first over-the-counter daily birth control pill approved by the FDA for all ages. Expected to be available in major retail locations and online within weeks, Opill® aims to provide improved access to contraceptive options, reducing barriers often associated with prescription requirements. The product's affordability, with a suggested retail price of under $20 per month, along with a forthcoming cost-assistance program, highlights Perrigo's commitment to empowering individuals in their reproductive health choices.
Read more →PRGOPerrigo to Attend UBS Global Consumer and Retail Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor...
Perrigo Company plc (NYSE: PRGO) has announced its participation in the UBS Global Consumer and Retail Conference on March 13, 2024. President and CEO Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will present at the event in New York City. The conference aims to enhance investor engagement and provide insights into the company's consumer self-care product offerings. This event underscores Perrigo's commitment to proactive health solutions.
Read more →PRGO▼ -15.1%on this newsshared move
Perrigo Reports Fourth Quarter Fiscal Year 2023 Financial Results From Continuing Operations Launches Investment Efficiency Program Net Sales from Continuing Operations Were a Fourth Quarter and Fiscal Year Record Delive
Perrigo Company plc announced its financial results for the fourth quarter and fiscal year 2023, indicating a record net sales of $1.2 billion for the quarter. The company reported an adjusted diluted EPS increase of 14.7% year-over-year. Perrigo is launching 'Project Energize', an investment efficiency initiative expected to generate significant long-term savings. However, challenges remain, particularly in the infant formula segment, as the company anticipates a moderate growth outlook for 2024 due to strategic transitions.
Read more →PRGOPerrigo Increases its Quarterly Dividend Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, announces that its Board of Directors has approved a 1%...
Perrigo Company plc (NYSE: PRGO) has announced a 1% increase in its quarterly dividend, raising it to $0.276 per share, or $1.10 annually. This marks the company's 21st consecutive year of dividend increases, showcasing a consistent commitment to shareholder returns. The dividend will be payable on March 26, 2024, to shareholders of record by March 8, 2024. This move reflects Perrigo's ongoing strength as a leading provider of Consumer Self-Care Products.
Read more →PRGOPerrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and...
Perrigo Company plc announced it will issue its fourth quarter and fiscal year 2023 financial results on February 27, 2024. A conference call will be held at 8:30 A.M. (EST) to discuss the results, and it will be accessible via webcast or phone. A replay of the call will be available shortly after the live event. This announcement aligns with Perrigo's focus on transparency in its business operations and investor relations.
Read more →PRGOPerrigo Announces Early Results of Cash Tender Offer for Notes DUBLIN
Perrigo Company plc has announced the early results of its cash tender offer for its 3.900% Senior Notes due 2024, aiming to purchase up to $300 million in notes. As of the early tender date, a total of approximately $385.5 million in notes have been tendered, with $300 million expected to be accepted for purchase. The settlement for these notes is anticipated to occur on December 15, 2023. The offer is contingent on the successful closing of a proposed financing of $300 million through incremental term loans.
Read more →PRGOPerrigo Announces Cash Tender Offer for Notes Perrigo Company plc (NYSE: PRGO) (the Company ), a leading provider of Consumer Self-Care Products, today announced that Perrigo Finance Unlimited...
Perrigo Company plc has announced a cash tender offer to purchase up to $300 million of its 3.900% Senior Notes due 2024. The company plans to finance the offer by borrowing an equivalent amount through incremental term loans. The completion of the tender offer is contingent on certain conditions, including the successful closing of the proposed financing. This strategy aims to enhance the company's financial flexibility and support its strategic plans.
Read more →PRGOPerrigo Announces Cash Tender Offer for Notes DUBLIN
Perrigo Company plc announced a cash tender offer to purchase up to $300 million of its 3.900% Senior Notes due in 2024. The financing for this tender will involve borrowing $300 million through incremental term loans. The move aims to enhance financial flexibility and meet near-term debt commitments. Potential risks include conditions that must be satisfied before the offer can be completed and uncertainty surrounding the proposed financing.
Read more →PRGOPerrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations Realized Third Quarter Double-Digit Gross Profit, Operating Income and EPS Growth Year-Over-Year Delivered Third Quarter Gross M
Perrigo Company plc reported its financial results for the third quarter of fiscal year 2023, showcasing a net sales increase of 2.2% year-over-year, reaching $1.1 billion. The company achieved significant growth in gross profit, operating income, and earnings per share (EPS), with reported EPS improving from a loss to $0.11. Adjusted EPS increased by 14.3%, reflecting strong operational fundamentals, though organic net sales faced challenges due to purposeful SKU prioritization and distributor transitions. Perrigo revised its fiscal 2023 sales growth outlook but maintained a positive long-term growth strategy under new CEO Patrick Lockwood-Taylor.
Read more →PRGOPerrigo to Attend Upcoming Consumer Investor Conferences Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Patrick Lockwood-Taylor...
Perrigo Company plc (NYSE: PRGO) announced that President and CEO Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will attend two upcoming consumer investor conferences. They are scheduled for one-on-one meetings at the Jefferies Consumer Conference in Miami, FL, on November 15, 2023, and will present at the Morgan Stanley Consumer & Retail Conference in New York City on December 6, 2023. The company's engagement with investors signals confidence and commitment to maintaining transparency and communication with stakeholders.
Read more →PRGOPerrigo to Release Third Quarter 2023 Financial Results on November 7, 2023 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2023...
Perrigo Company plc has announced that it will release its third quarter 2023 financial results on November 7, 2023, followed by a conference call at 8:30 A.M. (EST). The call will be accessible via webcast and phone for interested parties, with a replay available later. Perrigo emphasizes its commitment to transparency and investor engagement as a leading provider of consumer self-care products.
Read more →PRGOPerrigo Announces Leadership Update Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced the appointment of Catherine Triona Schmelter...
Perrigo Company plc appoints Catherine "Triona" Schmelter as Executive Vice President and President of Consumer Self-Care Americas and Global Portfolio Optimization. Her role involves leading growth and profitability for the CSCA business and overseeing global portfolio evolution. Schmelter comes with substantial experience, having previously held key positions in the consumer packaged goods sector. The announcement follows the departure of James E. Dillard III, who will pursue other opportunities.
Read more →PRGOPerrigo to Attend Upcoming Consumer Investor Conferences Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that CFO Eduardo Bezerra is scheduled to...
Perrigo Company plc (NYSE: PRGO) has announced that CFO Eduardo Bezerra will take part in one-on-one investor meetings at the Barclays Global Consumer Staples Conference on September 7, 2023. Additionally, both Bezerra and CEO Patrick Lockwood-Taylor are scheduled to present at the Piper Sandler Growth Frontiers Conference on September 12, 2023. These events underline Perrigo's commitment to engaging with investors and showcasing its consumer self-care products.
Read more →PRGO▲ +8.5%on this news
Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations Achieved Year-Over-Year and Sequential Gross and Operating Margin Expansion Delivered Strong Operating Income and EPS Growth Re
Perrigo Company plc reported its financial results for the second quarter of fiscal year 2023, showcasing solid year-over-year growth. Net sales reached $1.2 billion, reflecting a 6.4% increase, driven largely by acquisitions and strategic pricing actions. The gross margin expanded by 270 basis points to 35.9%, while adjusted earnings per share rose 46.5% to $0.63. The company reaffirmed its 2023 sales and earnings outlook, despite facing challenges like SKU prioritization and regulatory pressures in the U.S. Nutrition segment.
Read more →PRGOPERRIGO ANNOUNCES QUARTERLY DIVIDEND Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a...
Perrigo Company plc has announced a quarterly dividend of $0.273 per share, which is set to be paid on September 19, 2023, to shareholders of record on September 1, 2023. This decision highlights the company's commitment to providing value to its shareholders. As a leading provider of consumer self-care products, Perrigo continues to support individual well-being. Shareholders are encouraged to stay informed about potential future dividends and associated risks through the company's SEC filings.
Read more →PRGOPerrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2023...
Perrigo Company plc (NYSE: PRGO) will issue its second quarter 2023 financial results on August 8, 2023. The company will also host a conference call at 8:30 A.M. (EST) to discuss these results. Additionally, President and CEO Patrick Lockwood-Taylor along with CFO Eduardo Bezerra will present at the Canaccord Genuity 43rd Annual Growth Conference in Boston on August 9. Webcast links for the events will be available on the company's investor relations website.
Read more →PRGOPerrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration (FDA) ...
Perrigo Company has announced that the FDA has approved Opill®, a progestin-only daily oral contraceptive, for over-the-counter use, making it the first of its kind available in the United States. This approval is seen as a transformative step for women's health, improving access to contraception for all ages. The decision follows unanimous recommendations from advisory committees highlighting the benefits of non-prescriptive contraceptive options. The pill is set to be available in stores and online in early 2024.
Read more →PRGOPerrigo Appoints Patrick Lockwood-Taylor as President and CEO Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced the appointment of industry professional Patrick ...
Perrigo Company plc has announced the appointment of Patrick Lockwood-Taylor as the new President and CEO, effective June 30, 2023. Previously, Lockwood-Taylor held significant roles at Bayer AG, achieving notable growth in North America. He brings over 25 years of experience in the consumer product sector and aims to further develop Perrigo's portfolio and operational execution. Chairman Orlando D. Ashford expressed confidence in Lockwood-Taylor's leadership abilities to execute the company's Optimize & Accelerate strategy effectively.
Read more →PRGOPerrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer Consumer Growth & E-Commerce Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it is scheduled to host 1x1 investor...
Perrigo Company plc (NYSE: PRGO) announced it will host 1x1 investor meetings at the Oppenheimer 23rd Annual Consumer Growth & E-Commerce Conference. This virtual event is set for June 13th, aiming to connect the company with potential investors. Perrigo highlights its role as a leading provider of consumer self-care products and OTC health solutions. The announcement reflects the company’s efforts to enhance investor relations.
Read more →PRGOPERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S....
Perrigo Company plc has announced that it has received final approval from the U.S. FDA for its Nicotine Coated Mint Lozenges, available in 2 mg and 4 mg doses, which will be marketed under retailer store brand labels. This product aims to assist consumers in quitting smoking by helping to reduce withdrawal symptoms. It is expected to be available for purchase online and in stores by early summer 2023. The approval reflects Perrigo's ongoing commitment to develop innovative self-care products that meet consumer preferences.
Read more →PRGOFDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration's...
Perrigo Company plc announced that the FDA Joint Advisory Committee has voted in favor of switching its Opill® daily oral contraceptive to over-the-counter (OTC) status. This decision is heralded as a significant advancement in reproductive health, potentially increasing access to contraceptive methods for U.S. women. The Opill® OTC program included rigorous studies demonstrating consumer understanding and correct usage. If approved, it will be the first oral contraceptive available OTC in the U.S., supported by data highlighting its safety and effectiveness.
Read more →PRGOPerrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations First Quarter 2023 Highlights First quarter net sales grew 10.0% versus the prior year quarter to $1.2 billion. Constant currenc
Perrigo Company plc reported strong financial results for the first quarter of fiscal year 2023, with net sales rising 10.0% to $1.2 billion. The adjusted diluted EPS showed a significant increase of 35.6%, though challenges from product recalls impacted this metric. The company successfully resolved a major IRS tax audit without incurring any payment, contributing to a positive outlook. Perrigo reaffirms its sales growth expectations for the fiscal year, aiming for organic net sales growth of 3.0% to 6.0% and total net sales growth of 7.0% to 11.0%. CEO Murray S. Kessler remains optimistic about the company's future direction amidst ongoing strategic initiatives.
Read more →PRGOPerrigo Announces Chief Executive Officer Retirement and Succession Plan Dublin, Ireland
Perrigo Company plc has announced that Murray S. Kessler will retire as CEO effective July 31, 2023. Under his leadership, Perrigo has undergone a significant transformation into a consumer self-care entity, achieving notable financial improvements. The Board is actively engaged in a succession plan to find a successor who will continue to execute on the company’s strategic objectives. Kessler expressed confidence in Perrigo's future growth prospects and the team's ability to deliver value for investors.
Read more →PRGOPerrigo to Release First Quarter 2023 Financial Results on May 9, 2023 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2023...
Perrigo Company plc has announced that it will release its financial results for the first quarter of 2023 on May 9, 2023. Alongside this release, a conference call will take place at 8:30 AM EST, which will be accessible via webcast and phone. The company is focused on consumer self-care products and emphasizes the importance of proactive health management. This news highlights Perrigo's ongoing commitment to transparency in its financial reporting.
Read more →PRGOPerrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral Contraceptive for OTC Use Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the U.S. Food and Drug Administration (FDA) ...
Perrigo Company plc has announced the rescheduling of a joint FDA Advisory Committee meeting to review its application for the Opill® daily oral contraceptive to be sold over-the-counter. Scheduled for May 9 and 10, 2023, this meeting will discuss the potential for Opill® to be the first OTC daily birth control pill available in the U.S. The application, initially filed in July 2022 by Perrigo's HRA Pharma affiliate, has garnered support from several prominent medical organizations. However, the approval process remains uncertain, with no guarantees on the timing or outcome of the FDA's decisions.
Read more →PRGOPerrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Murray S. Kessler and...
Perrigo Company plc (NYSE: PRGO) has announced that its President and CEO, Murray S. Kessler, along with CFO Eduardo Bezerra, will present at the 12th Annual UBS Global Consumer and Retail Conference in New York City on March 15. This event represents an opportunity for the company to communicate its business strategies and engage with investors. The press release emphasizes Perrigo's leading role in the health and wellness sector while cautioning that forward-looking statements may involve risks and uncertainties that could impact actual results.
Read more →PRGOPerrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S....
Perrigo Company plc has received FDA approval for its OTC product, Acetaminophen and Ibuprofen Tablets, which is the store brand equivalent of Advil Dual Action Tablets. This new offering is expected to launch by Spring 2023 and aims to provide effective pain relief by combining both acetaminophen and ibuprofen. The approval marks an important milestone for Perrigo, reinforcing its regulatory and developmental strengths and aligning with national brand innovation. Retail sales for the national brand equivalent were approximately $69 million in the past year, indicating strong market interest.
Read more →PRGOPerrigo Reports Fourth Quarter Fiscal Year 2022 Financial Results From Continuing Operations Highlights Perrigo fiscal year net sales grew 7.6% versus the prior year to $4.5 billion. Constant currency net sales (1) incre
Perrigo Company plc announced its financial results for the fourth quarter and fiscal year 2022, showing a 7.6% increase in net sales compared to the previous year, totaling $4.5 billion. The company achieved record net sales in both its Consumer Self-Care Americas and International segments, with adjusted gross margin improvements. However, the fourth quarter reported a loss per share of ($0.09) due to increased amortization and acquisition-related expenses. Perrigo also highlighted successful navigation through significant operational challenges, including supply chain disruptions.
Read more →PRGOPerrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day Perrigo Company plc (NYSE: PRGO) announced that it will outline its plans to drive long-term profitable growth and build shareholder value at today's ...
Perrigo Company plc has launched its 3-Year Optimize and Accelerate Strategic Plan during its Virtual Investor Day, outlining plans to drive long-term profitable growth while enhancing shareholder value. The company aims to achieve an annual target of 3% organic net sales growth and reduce its net leverage to below 3 times adjusted EBITDA by the end of 2025. Perrigo has invested significantly in new product development and infrastructure, and it is focused on improving its gross margins through various initiatives. The leadership articulated optimism around its self-care strategy and the growth potential in emerging markets.
Read more →PRGOPerrigo Increases its Quarterly Dividend Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors approved a 5% ...
Perrigo Company plc (NYSE: PRGO) announced a 5% increase in its quarterly dividend, raising it to $0.273 per share. This marks the company's 20th consecutive year of increasing dividends, demonstrating a strong commitment to returning value to shareholders. The cash dividend will be payable on March 28, 2023, to shareholders of record as of March 10, 2023. The company's forward-looking statements acknowledge potential uncertainties that could affect future results.
Read more →PRGOPerrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and...
Perrigo Company plc (NYSE: PRGO) announced plans to release its fourth quarter and fiscal year 2022 financial results on February 27, 2023. In conjunction with this, the company will host a Virtual Investor Day on February 28, 2023, starting at 8:00 AM EST. Interested parties are encouraged to register in advance to access the event. The announcement comes with a reminder of the company's forward-looking statements, highlighting the potential risks and uncertainties that could impact its financial outcomes.
Read more →PRGOPerrigo to Host Virtual Investor Day on February 28, 2023 Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that it will host a Virtual Investor Day...
DUBLIN , Dec. 19, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading global provider of Consumer Self-Care Products, today announced that it will host a Virtual Investor Day on February 28, 2023 , in conjunction with its regular quarterly earnings. At that meeting,
Read more →PRGO▼ -15.3%on this news
Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations Highlights Perrigo achieved third quarter net sales of $1.1 billion, an increase of 5.5%, or 12.3% excluding the impact of curre
Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations Perrigo achieved third quarter net sales of $1.1 billion, an increase of 5.5%, or 12.3% excluding the impact of currency translation, versus the prior year quarter. Year-to-date net sales
Read more →PRGOPerrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant Formula Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ) today announced a $170 million strategic investment to expand and strengthen its U.S....
Company Purchases Nestlé's Gateway Infant Formula Plant in Eau Claire, Wisconsin , along with U.S. and Canadian rights to the Good Start ® Infant Formula Brand Will Immediately Invest in Gateway Plant to Add 7 Million Pounds of Needed Capacity to the Infant Formula Industry and
Read more →PRGOPerrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter (OTC) Use Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading provider of Consumer Self-Care Products, today announced that it has...
DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ) ("Perrigo" or "the Company"), a leading provider of Consumer Self-Care Products, today announced that it has received notification that the U.S. Food and Drug Administration (FDA) has postponed the joint mee
Read more →PRGOPerrigo to Release Third Quarter 2022 Financial Results on November 8, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its third quarter 2022...
DUBLIN , Oct. 25, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022 . The Company will also host a conference call b
Read more →PRGOPERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the U.S. Food and Drug Administration (FDA) ...
DUBLIN , Sept. 12, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and
Read more →PRGO▼ -5.3%on this news
PERRIGO RELEASES STATEMENT ON RECENT MARKET TRADING ACTIVITY In response to speculative commentary regarding ranitidine (Zantac®) litigation from a news story that contained certain misleading and inaccurate...
DUBLIN , Aug. 17, 2022 /PRNewswire/ -- In response to speculative commentary regarding ranitidine (Zantac ® ) litigation from a news story that contained certain misleading and inaccurate information, Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Pro
Read more →PRGOPERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Second Quarter 2022 Highlights Perrigo achieved second quarter net sales of $1.1 billion, an increase of 14.3%, or 20.2% exclud
PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Second Quarter 2022 Highlights Perrigo achieved second quarter net sales of $1.1 billion, an increase of 14.3%, or 20.2% excluding the impact of currency translation, versus the prior y
Read more →PRGOPERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its second quarter 2022...
DUBLIN , July 27, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022 . The Company will also host a conference call be
Read more →PRGOPerrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that HRA Pharma, a Perrigo company, has...
DUBLIN and ALLEGAN, Mich. , July 11, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading global provider of Consumer Self-Care Products, today announced that HRA Pharma, a Perrigo company, has submitted its application to the United States Food and Drug Administrati
Read more →PRGOPERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER Perrigo Company plc (NYSE: PRGO) today announced that Ms. Alison Ives has been promoted to Executive Vice President and Chief Scientific Officer. In...
DUBLIN , June 1, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ) today announced that Ms. Alison Ives has been promoted to Executive Vice President and Chief Scientific Officer. In this role, Ms. Ives will be responsible for providing global oversight and coordination of P
Read more →PRGOPERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OMEPRAZOLE MAGNESIUM DELAYED-RELEASE MINI CAPSULES Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S....
DUBLIN , May 26, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg
Read more →PRGOPERRIGO TO PRESENT AT UPCOMING CONSUMER INVESTOR CONFERENCES Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Murray S. Kessler and...
DUBLIN , May 19, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Murray S. Kessler and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Credit Suisse HAL
Read more →PRGOPERRIGO ANNOUNCES PLANNED LEADERSHIP SUCCESSION Mr. Eduardo G. Bezerra named EVP, Chief Financial Officer Mr. Todd Kingma to retire after 19 years of service; Ms. Kyle L. Hanson to be named EVP, General Counsel and Corpo
PERRIGO ANNOUNCES PLANNED LEADERSHIP SUCCESSION Mr. Eduardo G. Bezerra named EVP, Chief Financial Officer Mr. Todd Kingma to retire after 19 years of service; Ms. Kyle L. Hanson to be named EVP, General Counsel and Corporate Dublin, Ireland May 11, 2022 Perrigo Company plc (NY
Read more →PRGOPERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCE Highlights Perrigo achieved first quarter net sales of $1.1 billion, an increase of 6.4% versus the prior year
PERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCE Perrigo achieved first quarter net sales of $1.1 billion, an increase of 6.4% versus the prior year quarter. Organic(1) net sales increased 9.7%, led by continued strong
Read more →PRGOPERRIGO ANNOUNCES PLANNED LEADERSHIP SUCCESSION
Mr. Eduardo G. Bezerra named EVP, Chief Financial Officer Mr. Todd Kingma to retire after 19 years of service; Ms. Kyle L. Hanson to be named EVP, General Counsel and Corporate Secretary DUBLIN, May 11, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider o
Read more →PRGOPERRIGO ANNOUNCES QUARTERLY DIVIDEND
DUBLIN, May 5, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.26 per share, payable on June 21, 2022, to shareholders of record on Jun
Read more →PRGOPERRIGO COMPLETES THE ACQUISITION OF HRA PHARMA Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that on April 29, 2022 it completed the...
DUBLIN , May 2, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products , today announced that on April 29, 2022 it completed the previously announced acquisition of Héra SAS ("HRA") for €1.8 billion, or approximately $1.9 billion
Read more →PRGOPERRIGO COMPLETES THE ACQUISITION OF HRA PHARMA Dublin, Ireland
PERRIGO COMPLETES THE ACQUISITION OF HRA PHARMA Dublin, Ireland May 2, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that on April 29, 2022 it completed the previously announced acquisition of H ra SAS ( HRA ) for 1.8
Read more →PRGOPERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA Dublin, Ireland
PERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA Dublin, Ireland April 28, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the closing date of the previously announced acquisition of H ra SAS ( HRA or
Read more →PRGOPERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the closing date of the previously...
DUBLIN , April 28, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products, today announced that the closing date of the previously announced acquisition of Héra SAS ("HRA" or "HRA Pharma") is expected to occur on April 29, 2022 ,
Read more →PRGOPERRIGO TO RELEASE FIRST QUARTER 2022 FINANCIAL RESULTS ON MAY 11, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it will release its first quarter 2022...
DUBLIN , April 27, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products, today announced that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022 . The Company will also host a conference call be
Read more →PRGOPERRIGO ANNOUNCES CLOSING OF $2.6 BILLION SENIOR SECURED CREDIT FACILITIES Dublin, Ireland
PERRIGO ANNOUNCES CLOSING OF $2.6 BILLION SENIOR SECURED CREDIT FACILITIES Dublin, Ireland April 20, 2022 Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading provider of Consumer Self-Care Products, today announced that it closed its previously announced seni
Read more →PRGOPERRIGO ANNOUNCES LAUNCH OF PRIVATE NOTES OFFERING Dublin, Ireland
PERRIGO ANNOUNCES LAUNCH OF PRIVATE NOTES OFFERING Dublin, Ireland - April 4, 2022 Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading provider of Quality, Affordable Self-Care Products, today announced that it has launched a private offering (the Offering )
Read more →PRGONon GAAP Disclosure The following provides a reconciliation of pro forma EBITDA and pro forma Adjusted EBITDA to pro forma net income (loss), which is the most directly comparable financial measure prepared in accordance
The following provides a reconciliation of pro forma EBITDA and pro forma Adjusted EBITDA to pro forma net income (loss), which is the most directly comparable financial measure prepared in accordance with GAAP: Pro Forma Twelve months ended December 31, 2021 in millions (un
Read more →PRGOPERRIGO ANNOUNCES LAUNCH OF SYNDICATION OF NEW SENIOR SECURED CREDIT FACILITIES Perrigo Company plc (NYSE: PRGO) ( Perrigo or the Company ), a leading provider of Quality, Affordable Self-Care Products, today announced that it...
DUBLIN , March 28, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ) ("Perrigo" or the "Company"), a leading provider of Quality, Affordable Self-Care Products, today announced that it has launched the syndication of new senior secured credit facilities expected to consist o
Read more →PRGOPERRIGO ANNOUNCES CFO RETIREMENT AND TRANSITION PLAN Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced the planned retirement of Ray Silcock, Executive ...
DUBLIN , March 24, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO ), a leading provider of Consumer Self-Care Products, today announced the planned retirement of Ray Silcock , Executive Vice President and Chief Financial Officer, who will remain with the company in his curr
Read more →PRGOPERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OTC USE OF NASONEX® 24HR ALLERGY
DUBLIN, March 17, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex® 24HR Alle
Read more →PRGOPERRIGO COMPLETES DIVESTITURE OF LATIN AMERICAN BUSINESSES
DUBLIN, March 10, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Quality Affordable Self-Care Products, today announced that it has completed the previously announced sale of its Mexico and Brazil-based over-the-counter (OTC) businesses to Advent Int
Read more →PRGOPERRIGO REPORTS FOURTH QUARTER FISCAL YEAR 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Highlights Fourth quarter net sales grew 4.9%, or 5.7% excluding the impact of currency, compared to the prior year to $1.1 bil
PERRIGO REPORTS FOURTH QUARTER FISCAL YEAR 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Fourth quarter net sales grew 4.9%, or 5.7% excluding the impact of currency, compared to the prior year to $1.1 billion led by a strong rebound in the demand for cough cold products. F
Read more →PRGOPERRIGO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
DUBLIN, Feb. 25, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) today announced that President and CEO, Murray S. Kessler and CFO Ray Silcock are scheduled to present at the Raymond James 43rd Annual Institutional Investors Conference at 11:00 AM EST on Tuesday, March 8th
Read more →PRGOPERRIGO TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ON MARCH 1, 2022
DUBLIN, Feb. 15, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and fiscal year 2021 financial results on Tuesday, March 1, 2022. The Company will also host a conference call beginning at 8:30 A.M. (EST). The c
Read more →PRGOPERRIGO TO PRESENT VIRTUALLY AT THE 40th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
DUBLIN, Jan. 4, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), announced today that President and CEO, Murray S. Kessler is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 PM (EST). Interest
Read more →PRGOPerrigo Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE)
DUBLIN, Nov. 22, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it is taking steps to voluntarily delist the Company's ordinary shares from trading on the Tel Aviv Stock Exchange (TASE). Perrigo
Read more →PRGO▼ -11%on this news
PERRIGO REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Major Strategic Initiatives Completed During Q3 - Closed sale of Rx business for $1.6B - Announced Acquisition of HRA Pharma for 1.8B - Sett
PERRIGO REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Major Strategic Initiatives Completed During Q3 - Closed sale of Rx business for $1.6B - Announced Acquisition of HRA Pharma for 1.8B - Settled 1.6B Irish Tax Assessment for Net Cash Outlay of 266
Read more →PRGORolf A. Classon To Not Stand for Re-Election as Chairman of The Perrigo Board of Directors
DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality Affordable Self-Care Products, today announced that Rolf A. Classon, Chairman of the Board of Perrigo Company plc, informed the Board that he intends to not stand for re-ele
Read more →PRGOPerrigo To Release Third Quarter 2021 Financial Results On November 10, 2021
DUBLIN, Oct. 27, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter 2021 financial results on Wednesday, November 10, 2021. The Company will also host a conference call beginning at 8:30 A.M. (EST). The conference c
Read more →PRGOPerrigo Announces New Consumer Self-Care Americas (CSCA) Leadership
DUBLIN, Oct. 5, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) ("Perrigo" or the "Company"), a leading provider of consumer self-care products, today announced that Jim Dillard, currently Executive Vice President ("EVP") and Chief Scientific Officer, has been named E
Read more →PRGOPerrigo Resolves Irish Tax Assessment for €297 million
DUBLIN, Sept. 29, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) ("Perrigo" or the "Company"), a leading provider of Quality, Affordable Self-Care Products, today announced that it has reached a settlement with the Irish Office of the Revenue Commissioners for the No
Read more →PRGO▲ +9%on this news
FOR RELEASE Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma Transaction would complete Perrigo s three-year transformation plan to become a global leader in consumer self-care; positions Perrigo to deli
Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma Dublin, Ireland September 8, 2021 Perrigo Company plc (NYSE, TASE: PRGO) ( Perrigo or the Company ) today announced that it has signed a binding offer to acquire H ra SAS ( HRA or HRA Pharma ), a leading global c
Read more →PRGO▲ +9%on this news
Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma
DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) ("Perrigo" or the "Company") today announced that it has signed a binding offer to acquire Héra SAS ("HRA" or "HRA Pharma"), a leading global consumer self-care company, from funds affiliated with privat
Read more →PRGOPerrigo To Host Virtual Investor Meetings At The 2021 Barclays Global Consumer Staples Conference
DUBLIN, Sept. 3, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that Perrigo President and CEO, Murray S. Kessler, and CFO, Ray Silcock, are scheduled to participate in investor meetings at the Barclays Global Consumer Staples Conference on Thursday,
Read more →PRGO▼ -12.6%on this news
PERRIGO REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Fiscal 2021 Net Sales Guidance Reaffirmed Adjusted EPS Now Expected Towards the Lower End of the Guidance Range due to Lower Sales Volumes
PERRIGO REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Fiscal 2021 Net Sales Guidance Reaffirmed Adjusted EPS Now Expected Towards the Lower End of the Guidance Range due to Lower Sales Volumes and Higher Input Costs U.S. and E.U. Consumer Self-Care T
Read more →PRGOPerrigo To Release Second Quarter 2021 Financial Results On August 11, 2021
DUBLIN, July 28, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter 2021 financial results on Wednesday, August 11, 2021. The Company will also host a conference call beginning at 8:00 A.M. (EDT). The conference ca
Read more →PRGOUNAUDITED PRO FORMA FINANCIAL INFORMATION (In millions, except share information) On
UNAUDITED PRO FORMA FINANCIAL INFORMATION (In millions, except share information) On July 6, 2021 Perrigo Company plc ( Perrigo or the Company ) completed the previously announced divestiture of its generic RX Pharmaceuticals business ( RX Business ) to Altaris Capital Partner
Read more →PRGOPerrigo Completes Divestiture Of Generic Rx Business For $1.55 Billion
DUBLIN, July 6, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, announced today that it has completed the previously announced sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC f
Read more →PRGOPerrigo To Present Virtually At Upcoming Consumer Investor Conferences
DUBLIN, May 21, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that that President and CEO, Murray S. Kessler and CFO, Ray Silcock are scheduled to participate in investor meetings at the Barclays Consumer Spring Symposium on Tuesday, May 25. Also,
Read more →PRGOPerrigo Divests Latin American Businesses
DUBLIN, May 18, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has reached a definitive agreement to sell its Mexico and Brazil-based over-the-counter (OTC) businesses to Advent International. This transaction, which is expected to close in th
Read more →PRGOFOR RELEASE PERRIGO REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Consumer Transformation Nearing Completion Ahead of Schedule Rx Transaction On-Track to Close in Q3'21 Rx Segment Now Reported i
PERRIGO REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS Consumer Transformation Nearing Completion Ahead of Schedule Rx Transaction On-Track to Close in Q3'21 Rx Segment Now Reported in Discontinued Operations 2021 Guidance Reaffirmed Dublin, Ireland -
Read more →PRGOPerrigo Reports First Quarter 2021 Financial Results From Continuing Operations
DUBLIN, May 11, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quarter of fiscal year 2021 ended April 3, 2021. The Consumer Self-Car
Read more →PRGOPerrigo To Release First Quarter 2021 Financial Results On May 11, 2021
DUBLIN, April 27, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its fiscal first quarter financial results on Tuesday, May 11, 2021. The Company will also host a conf
Read more →PRGOPERRIGO REPORTS FOURTH QUARTER FISCAL YEAR 2020 FINANCIAL RESULTS Consumer Transformation Ahead of Plan Consolidated fiscal 2020 net sales (1) increased 5.0% compared to the prior year to $5.1 billi
PERRIGO REPORTS FOURTH QUARTER FISCAL YEAR 2020 FINANCIAL RESULTS Consumer Transformation Ahead of Plan Consolidated fiscal 2020 net sales(1) increased 5.0% compared to the prior year to $5.1 billion, despite a 2.5% decline in the fourth quarter due primarily to lower net sales
Read more →PRGOPerrigo Reports Fourth Quarter & Fiscal Year 2020 Financial Results
DUBLIN, March 1, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2020. President and CEO, Murray S. Kessler comm
Read more →PRGOPerrigo Announces Agreement To Sell Generic Rx Business For $1.55 Billion In Total Consideration
DUBLIN, March 1, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, announced today that it has reached a definitive agreement to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for
Read more →PRGOPerrigo Increases Quarterly Dividend By 7%
DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that its Board of Directors approved a 7% increase in the Company's quarterly dividend to $0.24 per share from $0.225
Read more →PRGOPerrigo To Release Fourth Quarter And Calendar Year 2020 Financial Results On March 1, 2021
DUBLIN, Feb. 16, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2020 financial results on Monday, March 1, 2021. The Company will also host a conference call beginning at 8:00 a.m. (EST). The
Read more →PRGOPerrigo And Michigan State University Announce Partnership To Advance Consumer Self-Care Innovation
DUBLIN and GRAND RAPIDS, Mich., Jan. 11, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, announced today a formal partnership with Michigan State University (MSU), connecting the university's clinical and
Read more →PRGOPerrigo to Present Virtually at Upcoming Investor Conferences
DUBLIN, Dec. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that EVP and President of Consumer Self-Care Americas, Rich Sorota will present at the ICR Conference at 11:30 AM EST on Monday, January 11, 2021. Perrigo President & CEO Murray S. Kess
Read more →PRGOPerrigo To Present At The Morgan Stanley Global Consumer & Retail Conference
DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will present at the Morgan Stanley Global Consumer & Retail Conference at 1:00 PM EST on Tuesday, December 1, 2020. Intere
Read more →PRGOPerrigo Reports Third Quarter 2020 Financial Results
DUBLIN, Nov. 4, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced financial results for the third quarter ended September 26, 2020. President and CEO, Murray S. Kessler commented, "Results f
Read more →PRGOPERRIGO REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS Consolidated Third Quarter Net Sales Grew 1.3% (1) Led by CSCA Organic (2) Net Sales Growth of 4.0% GAAP ("Reported") Third Quarter Net Loss Per
PERRIGO REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS Consolidated Third Quarter Net Sales Grew 1.3%(1) Led by CSCA Organic(2) Net Sales Growth of 4.0% GAAP ("Reported") Third Quarter Net Loss Per Diluted Share of $1.13 Non-GAAP ("Adjusted") Third Quarter Earnings Per Diluted S
Read more →PRGOIrish High Court Rules Perrigo
DUBLIN, Nov. 4, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that the Irish High Court, which is a court of first instance, ruled that the issuance of the Notice of Amended Assessment by Irish Revenue in November 2018 did not violate the Company's l
Read more →PRGOPerrigo Completes Acquisition Of Market-Leading OTC Self-Care Brands In Eastern Europe
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it has completed the acquisition of three Eastern European OTC skincare and hair loss treatment brands, Emolium®,
Read more →PRGOPerrigo Updates Earnings Conference Call Timing Scheduled For November 4, 2020, Due To Notification Of Judical Review Decision
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has been advised by the Irish High Court that the Court's decision on our pending Judicial Review case on whether to
Read more →PRGOPerrigo To Release Third Quarter 2020 Financial Results On November 4, 2020
DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its third quarter financial results on Wednesday, November 4, 2020. The Company will also host a confer
Read more →PRGOPerrigo Voluntarily Recalls Albuterol Sulfate Inhalation Aerosol; Reaffirms 2020 Guidance
DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S. nationwide recall of albuterol sulfate inhalation aerosol to the retail level after previously halting production and distribution. These actions are being taken out of
Read more →PRGOPerrigo Announces The Store Brand Equivalent Of Voltaren® Arthritis Pain Is Available At U.S. Major Retailers Nationwide
DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has launched the store brand equivalent of over-the-counter ("OTC") Voltaren® Arthritis Pain (diclofenac sodium topical gel, 1%) to its retail partners and the product is now avai
Read more →PRGOPerrigo To Present At Upcoming Investor Conferences
DUBLIN, Ireland, Aug. 25, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host virtual one-on-one meetings at the
Read more →PRGOPerrigo Acquires Market-Leading OTC Self-Care Brands In Eastern Europe
DUBLIN, Aug. 11, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that it will acquire three Eastern European OTC skincare and hair loss treatment brands (Emolium®, Iwostin® and Loxon
Read more →PRGOFOR RELEASE PERRIGO COMPANY PLC REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Consolidated Second Quarter Reported Net Sales up 6.1% ; Organic (1) Net Sales Up 2.6% GAAP ("Reported") Second Quarter Diluted Earnings Per S
PERRIGO COMPANY PLC REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Consolidated Second Quarter Reported Net Sales up 6.1%; Organic(1) Net Sales Up 2.6% GAAP ("Reported") Second Quarter Diluted Earnings Per Share ("EPS") were $0.44 Non-GAAP ("Adjusted") Second Quarter EPS up 19.
Read more →PRGOPerrigo Company plc Reports Second Quarter 2020 Financial Results
DUBLIN, Aug. 5, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced financial results for the second quarter ended June 27, 2020. President and CEO Murray S. Kessler commented, "Strong second
Read more →PRGOPerrigo To Release Second Quarter 2020 Financial Results On August 5, 2020
DUBLIN, July 15, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its second quarter financial results on Wednesday, August 5, 2020. The Company will also host a confere
Read more →PRGOPerrigo Furthers Its Consumer-Focused Transformation By Divesting Its U.K. Generic Prescription Pharmaceuticals Business For £156 Million Or Approximately $195 Million
DUBLIN, June 19, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has reached a definitive agreement to sell its U.K.-based Rosemont Pharmaceuticals business, a generic prescription pharmaceuticals manufacturer focused on liquid medicines, to a
Read more →PRGOPerrigo Partners With Kazmira LLC To Enter CBD Market Through A Two-Phased, Science-Based Approach
DUBLIN, June 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it is entering the cannabidiol ("CBD") market through a strategic investment in and long-term supply agreement w
Read more →PRGOPerrigo Announces The Pricing Of A Senior Notes Offering By Its Finance Subsidiary, Perrigo Finance Unlimited Company
DUBLIN, June 16, 2020 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced the pricing of a previously announced registered public offering by Perrigo Finance Unli
Read more →PRGOPerrigo Announces Proposed Public Offering Of Senior Notes Of Its Finance Subsidiary, Perrigo Finance Unlimited Company
DUBLIN, June 16, 2020 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of P
Read more →PRGOPerrigo To Present At The 20th Annual Oppenheimer Consumer Growth & E-Commerce Virtual Conference
DUBLIN, Ireland, June 2, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that President and CEO Murray S. Kessler will present further details on the Company's consumer growth strategy along with a general update on the business at the 20th Annual Oppe
Read more →PRGOPerrigo Donates 160,000 Toothbrushes to West Michigan Nonprofit Organizations
GRAND RAPIDS, Mich., June 2, 2020 /PRNewswire/ -- As organizations struggle to meet increased demand for charitable relief during the COVID-19 pandemic, Perrigo Company is donating more than 160,000 toothbrushes to Camp Fire West Michigan, The StoreHouse of Community Resources an
Read more →PRGOPerrigo To Present At The RBC Capital Markets Global Healthcare Conference
DUBLIN, May 8, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that President and CEO Murray S. Kessler will host a fireside chat at the RBC Capital Markets Global Healthcare Conference at 11:30 AM EDT on Wednesday, May 20, 2020. Interested parties can
Read more →PRGOPerrigo To Present At The Goldman Sachs Global Staples Forum Webcast
DUBLIN, May 5, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that President and CEO Murray S. Kessler will present as part of the Goldman Sachs Global Staples Forum Webcast at 8:10 AM EST on Monday, May 18, 2020. Interested parties can access the pre
Read more →PRGOPERRIGO COMPANY PLC REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Reports Record First Quarter Consumer Self-Care Americas Net Sales Q1 GAAP ("Reported") Diluted Earnings Per Share ("EPS") of $0.77 a
PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Reports Record First Quarter Consumer Self-Care Americas Net Sales Q1 GAAP ("Reported") Diluted Earnings Per Share ("EPS") of $0.77 and Non-GAAP ("Adjusted") EPS of $1.14 Per Share Fiscal 2020 Adjusted Diluted EP
Read more →PRGOPerrigo Company plc Reports First Quarter 2020 Financial Results
DUBLIN, April 30, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced financial results for the first quarter ended March 28, 2020. President and CEO Murray S. Kessler commented, "During these unprecedented times, I am honored to be surrounded by our more
Read more →PRGOPerrigo Announces Change of Venue and Time of the Annual General Meeting to be Held on Wednesday, May 6, 2020 and Measures to Minimise Any Risk of Coronavirus (COVID-19) Transmission
DUBLIN, April 22, 2020 /PRNewswire/ -- The Perrigo Company plc (NYSE; TASE: PRGO) Board of Directors considers the well-being of shareholders, employees and service providers at the upcoming Annual General Meeting ("AGM") a primary concern and, in this context, has been closely m
Read more →PRGOPerrigo to Release First Quarter 2020 Financial Results on April 30, 2020
DUBLIN, April 16, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its first quarter financial results on Thursday, April 30, 2020. The Company will also host a conference call beginning at 8:30 a.m. (EST). The conference call will
Read more →PRGOPERRIGO ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER 2020 NET SALES AND PROVIDES FIRST QUARTER OPERATING INCOME RANGE Q1 2020 net sales growth of 14% versus prior year quarter Estimated Q1 GAAP operating income of $140
PERRIGO ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER 2020 NET SALES AND PROVIDES FIRST QUARTER OPERATING INCOME RANGE Q1 2020 net sales growth of 14% versus prior year quarter Estimated Q1 GAAP operating income of $140 million to $145 million and non-GAAP ("adjusted") operatin
Read more →PRGOPerrigo Announces FDA Approval for the Store Brand Equivalent of Voltaren® Arthritis Pain
DUBLIN, April 6, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it was the first to receive approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for over-the-counter ("OTC") diclofenac sodium topical
Read more →PRGOPerrigo Completes Acquisition of Oral Care Assets of High Ridge Brands
DUBLIN, April 2, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the acquisition of the oral self-care assets of High Ridge Brands. The acquisition underscores the numerous bolt-on opportunities that are advancing Perrigo's commit
Read more →PRGOPerrigo Company plc Reports Fourth Quarter & Fiscal Year 2019 Financial Results
DUBLIN, Feb. 27, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products™", today announced financial results for the fourth quarter and fiscal year ended December 31, 2019. President and CEO Murray S. Kes
Read more →PRGOPERRIGO COMPANY PLC REPORTS FOURTH QUARTER & FISCAL YEAR 2019 FINANCIAL RESULTS Reports Record Fourth Quarter Consumer Self-Care Americas Net Sales Transformation to Consumer Self-Care Company Remai
PERRIGO COMPANY PLC REPORTS FOURTH QUARTER & FISCAL YEAR 2019 FINANCIAL RESULTS Reports Record Fourth Quarter Consumer Self-Care Americas Net Sales Transformation to Consumer Self-Care Company Remains On-Track with Significant Progress Achieved in Fiscal Year 2019 Provides Fis
Read more →PRGOPerrigo and Catalent Announce FDA Approval of Perrigo
DUBLIN and SOMERSET, N.J., Feb. 24, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) and its partner, Catalent Pharma Solutions, today announced that the U.S. Food and Drug Administration (FDA) has approved Perrigo's abbreviated new drug application for generic albuter
Read more →PRGOPerrigo To Acquire Oral Care Assets Of High Ridge Brands
DUBLIN, Feb. 24, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has reached a definitive agreement to acquire the oral care assets of High Ridge Brands for $113 million in cash. The acquisition, which is subject to bankruptcy court approval in
Read more →PRGOPerrigo Increases its Dividend by 7%
DUBLIN, Feb. 18, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products™", today announced that its Board of Directors, consistent with its transformation into a consumer self-care company, approved a 7% i
Read more →PRGOPerrigo To Release Fourth Quarter And Calendar Year 2019 Financial Results On February 27, 2020
DUBLIN, Feb. 13, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2019 financial results on Thursday, February 27, 2020. The Company will also host a conference call beginning at 8:30 a.m. (EST).
Read more →PRGOPerrigo Announces Consumer Self-Care Americas Segment Leadership Transition
DUBLIN, Feb. 7, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of Quality, Affordable Self-Care Products™, today announced the future retirement of Jeff Needham, Executive Vice President and President, Consumer Self-Care Americas (CSCA). Ri
Read more →PRGOPERRIGO TO PROVIDE SELF-CARE TRANSFORMATION UPDATE AT J.P. MORGAN HEALTHCARE CONFERENCE; ANNOUNCES ROBUST PRELIMINARY UNAUDITED FOURTH QUARTER 2019 NET SALES Dublin, Ireland
PERRIGO TO PROVIDE SELF-CARE TRANSFORMATION UPDATE AT J.P. MORGAN HEALTHCARE CONFERENCE; ANNOUNCES ROBUST PRELIMINARY UNAUDITED FOURTH QUARTER 2019 NET SALES Dublin, Ireland - January 14, 2020 - Perrigo Company plc (NYSE; TASE: PRGO) Chief Executive Officer and President Murray
Read more →PRGOPerrigo Advances Consumer Self-Care Growth Strategy with Ranir Subsidiary Acquisition of Steripod® Toothbrush Accessory Brand
DUBLIN, Jan. 6, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that its Ranir subsidiary has acquired the assets of Steripod®, a leading toothbrush accessory brand and innovator in the toothbrush protector market, from Bonfit America Inc. The deal inc
Read more →PRGOPerrigo to Present at Upcoming Investor Conferences
DUBLIN, Dec. 18, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler will present at the ICR Conference at 9:30 AM EST on Monday, January 13, 2020 at the Grande Lakes Orlando Resort in Orlando, Florida. Mr. Kessl
Read more →PRGOPerrigo Announces Closing of Prevacid®24HR (OTC) Acquisition, Advancing Consumer Self-Care Growth Strategy
DUBLIN, Dec. 2, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the acquisition of the branded over-the-counter (OTC) rights to Prevacid®24HR. Jeff Needham, Executive Vice President and President Consumer Self-Care Americas said,
Read more →PRGOPerrigo to Present at the Morgan Stanley Global Consumer & Retail Conference
DUBLIN, Nov. 13, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will present at the Morgan Stanley Global Consumer & Retail Conference at 10:00 AM EST on Wednesday, December 4, 2019. Int
Read more →PRGOPerrigo Company plc Reports Third Quarter 2019 Financial Results
DUBLIN, Nov. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care ProductsTM", today announced financial results for the third quarter ended September 28, 2019. President and CEO Murray S. Kessler commented,
Read more →PRGOPERRIGO COMPANY PLC REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Continues Successful Transformation to a Consumer Self-Care Company Raises 2019 Adjusted EPS Guidance Dublin, Ireland
PERRIGO COMPANY PLC REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Continues Successful Transformation to a Consumer Self-Care Company Raises 2019 Adjusted EPS Guidance Dublin, Ireland - November 6, 2019 - Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Qua
Read more →PRGOPerrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product
DUBLIN, Oct. 23, 2019 /PRNewswire/ -- As a precautionary measure, Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). The recall is being taken due to possi
Read more →PRGOPerrigo Announces Third Quarter Calendar Year 2019 Earnings Date
DUBLIN, Oct. 15, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a conference call beginning at 8:00 a.m. (EDT). The con
Read more →PRGOPerrigo® Hosts 175 West Michigan Students for Manufacturing Week Celebration
ALLEGAN, Mich., Oct. 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", opened its doors for more than 175 high school students Thursday as part of Michigan Manufacturing Week. Attendees toured Perrigo'
Read more →PRGOPerrigo Announces the Relaunch of the AB Rated Generic Version of Transderm Scop® 1.5 MG
DUBLIN, Oct. 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and therapeutic equivalents for the 12 months ending August
Read more →PRGOPerrigo Advances Consumer Self-Care Growth Strategy With Acquisition Of Prevacid®24hr
DUBLIN, Sept. 5, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a definitive agreement to acquire the branded OTC rights to Prevacid® from GlaxoSmithKline. Under the terms of the agreement, Perrigo will have the exclusive righ
Read more →PRGOPerrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray
DUBLIN, Aug. 21, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc. Terms of the settlement are confidential. Annual m
Read more →PRGOPERRIGO COMPANY PLC REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS, REAFFIRMS OUTLOOK, PROGRESSES CONSUMER TRANSFORMATION GAAP ("reported") net sales were $1.15 billion , reflecting a 3% decline vers
PERRIGO COMPANY PLC REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS, REAFFIRMS OUTLOOK, PROGRESSES CONSUMER TRANSFORMATION Dublin, Ireland - August 8, 2019 - Perrigo Company plc (NYSE; TASE: PRGO) today announced financial results for the second quarter ended June 29, 2019. Presi
Read more →PRGOPerrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation
DUBLIN, Aug. 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.15 billion, reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased by approximately 1% excluding the unfavorable impact of currency and exited businesses. Second qu
Read more →PRGOPerrigo Announces Resignation Of Jeffrey C. Smith From Its Board Of Directors
DUBLIN, Aug. 7, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief Investment Officer of Starboard Value LP, who ha
Read more →PRGOPerrigo Announces Second Quarter Calendar Year 2019 Earnings Date
DUBLIN, July 25, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference call beginning at 8 a.m. (EDT). The conferen
Read more →PRGOPerrigo Completes Divestiture of Animal Health Business for $185 Million
DUBLIN, July 8, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (NASDAQ: PETQ) for $185 million. Perrigo CEO and President Murray S. Kessler stated, "Com
Read more →PRGOPerrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel
DUBLIN, July 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application ("ANDA") referencing Metrogel-Vaginal®
Read more →PRGOPerrigo Completes Acquisition Of Ranir, Raises Guidance
DUBLIN, July 2, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the successful completion of its acquisition of Ranir Global Holdings LLC ("Ranir"), the leading global store brand supplier of oral self-care products, for $750 million in cash. This tran
Read more →PRGOPerrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%
DUBLIN, May 21, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium top
Read more →PRGOPerrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day
DUBLIN, May 9, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today is holding its Investor Day at the New York Stock Exchange in New York City, outlining its strategy to drive long-term growth and build shareholder value. Chief Executive Officer and President Murray
Read more →PRGOPerrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products
DUBLIN, May 9, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750 million on a cash-free, debt-free basis, or approxi
Read more →PRGOPerrigo Company plc Reports First Quarter 2019 Financial Results, Begins Consumer Self-Care Transformation
DUBLIN, May 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.2 billion, reflecting a 4% decline versus the prior year period, or down 1% excluding the unfavorable impact of currency. First quarter reported diluted earnings per share ("EPS") decreased 18% versus last
Read more →PRGOPerrigo To Divest Animal Health Business For $185 Million In Cash As Part Of Consumer Self-Care Transformation
DUBLIN, May 8, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it has reached a definitive agreement to sell its Animal Health business to PetIQ (NASDAQ: PETQ) in a transaction valued at $185 million in cash. This transaction is consistent with P
Read more →PRGOPERRIGO COMPANY PLC SELECTED SEGMENT INFORMATION QUARTERS AND FISCAL YEAR 2016 (in millions) (unaudited) Three Months Ended Year Ended Consumer Self-Care Americas
SELECTED SEGMENT INFORMATION QUARTERS AND FISCAL YEAR 2016 Three Months Ended Year Ended Consumer Self-Care Americas April 2, 2016 July 2, 2016 October 1, 2016 December 31, 2016 December 31, 2016 Net sales $ 639.1 $ 629.9 $ 611.2 $ 626.8 $ 2,507.0 Gross profit $
Read more →PRGOPERRIGO COMPANY PLC REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS, BEGINS CONSUMER SELF-CARE TRANSFORMATION GAAP ("reported") net sales were $1.2 billion , reflecting a 4% decline versus the prior ye
PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS, BEGINS CONSUMER SELF-CARE TRANSFORMATION Dublin, Ireland - May 8, 2019 - Perrigo Company plc (NYSE; TASE: PRGO) today announced financial results for the first quarter ended March 30, 2019. Perrigo President and
Read more →PRGOPerrigo Announces First Quarter Calendar Year 2019 Earnings Date And Upcoming Conference Participation
DUBLIN, May 1, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its first quarter calendar year 2019 financial results on May 8, 2019 after market close in the U.S. and will discuss the results and 2019 guidance at its Investor Day
Read more →PRGOPerrigo Increases Its Dividend By 11%
DUBLIN, April 26, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that the company's Board of Directors, consistent with its recently approved strategic plan to evolve to a consumer self-care company, approved an 11% increase to the company's quarterl
Read more →PRGOPerrigo To Host Investor Day
DUBLIN, April 18, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of Quality, Affordable Self-Care Products™, today announced that it will hold its Investor Day on May 9 in New York City to discuss its strategy and key growth opportunities.
Read more →PRGOPerrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%
DUBLIN, April 4, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Sernivo®
Read more →PRGOPerrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%
DUBLIN, April 2, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™", today announced that it has settled its Hatch-Waxman litigation relating to its tentatively-approved generic version of Finacea® F
Read more →PRGOPerrigo Appoints Seasoned CPG Veteran Ray Silcock As Chief Financial Officer
DUBLIN, March 20, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ray Silcock will join the Company as Executive Vice President and Chief Financial Officer, effective March 25, 2019. Ray will lead the global finance, tax, internal audit, investor
Read more →PRGOPerrigo Announces Tentative FDA Approval For The Generic Version Of Finacea® Foam, 15%
DUBLIN, March 18, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™" today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Finacea®
Read more →PRGOPerrigo Confirms Patent Challenge for Generic Version of Nascobal®
DUBLIN, March 5, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Endo Pharmaceuticals Inc. initiated patent litigation on March 1, 2019 in the United States District Court for the District of Delaware regarding Perrigo's Paragraph IV Abbreviated N
Read more →PRGOPERRIGO COMPANY PLC REPORTS 2018 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS Full-year 2018 GAAP ("Reported") net sales of $4.7 billion , reflecting a 4% decline versus a year ago; Fourth quarter
PERRIGO COMPANY PLC REPORTS 2018 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS Dublin, Ireland - February 27, 2019 - Perrigo Company plc (NYSE; TASE: PRGO) today announced financial results for the fourth quarter and calendar year ended December 31, 2018. Perrigo President and
Read more →PRGOPerrigo Company plc Reports Fourth Quarter And Full-Year 2018 Financial Results
DUBLIN, Feb. 27, 2019 /PRNewswire/ -- Full-year 2018 GAAP ("Reported") net sales of $4.7 billion, reflecting a 4% decline versus a year ago; Fourth quarter 2018 reported net sales of $1.2 billion, a 7% decline versus the prior year. Full-year 2018 Worldwide Consumer businesses
Read more →PRGOPerrigo Receives Leave To Judicially Review Irish Revenue Tax Assessment
DUBLIN, Feb. 25, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced that its subsidiary, Perrigo Pharma International DAC ("Elan Pharma"), has been granted leave by the Irish High C
Read more →PRGOPerrigo Company plc To Release Fourth Quarter And Calendar Year 2018 Results On February 27, 2019
DUBLIN, Feb. 13, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that it will release its fourth quarter and calendar year 2018 financial results on Wednesday, February 27, 2019.
Read more →PRGOPerrigo Announces Patent Litigation Settlement for the Generic Version of Jublia® Topical Solution 10%
DUBLIN, Feb. 13, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that it has settled its Hatch-Waxman litigation relating to its first-to-file Abbreviated New Drug Application for
Read more →PRGOPerrigo Announces FDA Final Approval for its AB Rated Generic Version of Zovirax® Cream 5%
DUBLIN, Feb. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Zovirax® Cream, 5% (acyclovir cream, 5%) developed i
Read more →PRGOPerrigo To Receive Milestone Payment Of $250 Million From RPI Finance Trust
DUBLIN, Jan. 29, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of "Quality, Affordable Self-care Products™", today announced that the company expects to receive a milestone payment of $250 million from RPI Finance Trust, an affiliate of Ro
Read more →PRGOPerrigo Appoints James Dillard To Role Of Chief Scientific Officer
DUBLIN, Jan. 14, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that James Dillard has been appointed Executive Vice President and Chief Scientific Officer. In this new role, Jim will be responsible for providing global oversight and coordination of P
Read more →PRGOPERRIGO COMPANY PLC INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Perrigo Company plc
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District for the Southern District of New York against Perrigo Company plc ("Perrigo" or the "Compan
Read more →PRGOPerrigo To Present At The J.P. Morgan Global Healthcare Conference
DUBLIN, Dec. 20, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that President and CEO Murray Kessler will present at the 37th Annual J.P. Morgan Global Healthcare Conference at 5:00 PM EST on Tuesday, January 8, 2019 at the Westin St. Francis Hotel i
Read more →PRGOPerrigo Announces the Launch of an AB Rated Generic Version of Topicort® Topical Spray 0.25%
DUBLIN, Dec. 10, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%. Topicort® Topical Spray is indicated for the treatment of plaque psoriasis in patients 18 year
Read more →PRGOPerrigo Announces Patent Litigation Settlement For The Generic Version Of Sernivo® Spray, 0.05%
DUBLIN, Nov. 28, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate, 0.05%) Spray brought by Promius Pharma LLC. Terms of the settlement are confidential. Se
Read more →PRGOPerrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%
DUBLIN, Nov. 27, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its AB rated abbreviated new drug application referencing Solaraze® Gel, 3% (diclofenac sodium gel, 3%). Solaraze® Gel, 3% is indicated for the topical treatment of actin
Read more →PRGOPerrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate® Lotion 0.05%
DUBLIN, Nov. 26, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the first to file generic version of Ultravate® Lotion (halobetasol propionate) 0.05%. Perrigo previously
Read more →PRGOPERRIGO COMPANY PLC REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS Realized third quarter 2018 GAAP ("reported") net sales of $1.1 billion , reported net loss of $68 million compared to a net income o
PERRIGO COMPANY PLC REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS Dublin, Ireland - November 8, 2018 - Perrigo Company plc (NYSE; TASE: PRGO) today announced financial results for the third quarter ended September 29, 2018. Refer to Tables I - VI at the end of this press release
Read more →PRGOPerrigo Company plc Reports Third Quarter 2018 Financial Results
DUBLIN, Nov. 8, 2018 /PRNewswire/ -- Realized third quarter 2018 GAAP ("reported") net sales of $1.1 billion, reported net loss of $68 million compared to a net income of $45 million last year and reported diluted loss per share of $0.49 compared to net earnings per share ("EPS"
Read more →PRGOPerrigo Confirms Patent Challenge For Generic Version Of Kerydin®
DUBLIN, Oct. 29, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Anacor Pharmaceuticals, Inc., initiated patent litigation on October 25, 2018 in the United States District Court for the District of Delaware regarding Perrigo's Paragraph IV Abbrev
Read more →PRGOPerrigo Confirms Patent Challenge For Generic Version Of Narcan®
DUBLIN, Oct. 26, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Ltd. and Opiant Pharmaceuticals initiated patent litigation on October 25, 2018 in the United States District Court f
Read more →PRGOPerrigo To Release Third Quarter Calendar Year 2018 Financial Results On November 8, 2018
DUBLIN, Oct. 25, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter calendar year 2018 financial results on Thursday, November 8, 2018. The Company will host a conference call beginning at 8:30 a.m. (EST). The confe
Read more →PRGOPerrigo Announces The Launch Of An AB Rated Generic Version Of Androgel® Topical Gel, 1.62%
DUBLIN, Oct. 15, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Androgel® Topical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g packet, and 20.25mg/1.25g actuation pump). At generi
Read more →PRGOPerrigo Appoints Murray S. Kessler As President And Chief Executive Officer In Line With Shift To Consumer-Focused Strategy
DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Murray S. Kessler, former Chief Executive Officer and President at the Lorillard Tobacco Company, appointed President, CEO and member of the Board of Directors effective immediately Proven track record for over 30 years in leadership positio
Read more →PRGOPerrigo Confirms Patent Challenge for Generic Version of Jublia® Topical Solution 10%
DUBLIN, Oct. 1, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that, Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., Dow Pharmaceuticals Sciences, Inc., and Kaken Pharmaceuticals Co., LTD, initiated patent litigation o
Read more →PRGOPerrigo Announces Patent Litigation Settlement for the Generic Version of Picato® Gel
DUBLIN, Sept. 28, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Picato® (ingenol mebutate) gel, 0.015%, 0.05% brought by LEO Pharma Inc., LEO Pharma A/S, and LEO Laboratories Limited. Terms
Read more →PRGOPerrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Imodium® Multi-Symptom Relief
DUBLIN, Sept. 7, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium® Multi-Symptom Relief (loperamide hydrochlori
Read more →PRGOPerrigo to Reschedule Investor Event
DUBLIN, Aug. 29, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously planned as a conference call for September 25, 201
Read more →PRGOPerrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
DUBLIN, Aug. 9, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the United States to pursue regulatory approval for a
Read more →PRGOPerrigo Announces Plan To Separate Prescription Pharmaceuticals Business
DUBLIN, Aug. 9, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors approved a plan to separate the Company's Prescription Pharmaceuticals (Rx) business following the Company's previously announced strategic portfolio review. Co
Read more →PRGOPerrigo Company plc Reports Second Quarter 2018 Financial Results
DUBLIN, Aug. 9, 2018 /PRNewswire/ -- Realized second quarter 2018 GAAP ("reported") net sales of $1.2 billion, reported net income of $36 million compared to a net loss of $70 million last year and reported diluted earnings per share ("EPS") of $0.26 compared to losses per share
Read more →PRGOPERRIGO COMPANY PLC REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS Realized second quarter 2018 GAAP ("reported") net sales of $1.2 billion , reported net income of $36 million compared to a net loss
PERRIGO COMPANY PLC REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS range of $2.11 to $2.31 and calendar year 2018 adjusted diluted EPS in the range of $4.75 to $4.95; see Guidance section below for details Dublin, Ireland - August 9, 2018 - Perrigo Company plc (NYSE; TASE: PRGO)
Read more →PRGOPerrigo To Release Second Quarter Calendar Year 2018 Financial Results On August 9, 2018
DUBLIN, July 26, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter calendar year 2018 financial results on Thursday, August 9, 2018. The Company will host a conference call beginning at 8:30 a.m. (EDT). The confer
Read more →PRGOYou Don't Need Sun to Feel the Burn This Summer Summer† is the perfect time for beach days, tropical vacations, outdoor barbecues … and frequent heartburn*, according to a new survey commissioned...
ALLEGAN, Mich., June 5, 2018 /PRNewswire/ -- Summer† is the perfect time for beach days, tropical vacations, outdoor barbecues … and frequent heartburn*, according to a new survey commissioned by Perrigo Company plc, producers of store brand Omeprazole Delayed Release Orally Disi
Read more →PRGOPerrigo to Present at the Jefferies 2018 Healthcare Conference
DUBLIN, May 30, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the Jefferies 2018 Healthcare Conference at 8:30 AM EST on Tuesday, June 5, 2018. Interested parties can access the pr
Read more →PRGOPerrigo Confirms Patent Challenge For Generic Version Of Sernivo® Spray, 0.05%
DUBLIN, May 24, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that Promius Pharma LLC initiated patent litigation on May 22, 2018 in the U.S. District Court for the Eastern District of Texas, regarding Perrigo's Paragraph IV Abbreviated New Drug Appl
Read more →PRGOPerrigo Confirms First To File Patent Challenge For Generic Version Of Ultravate® Lotion, 0.05%
DUBLIN, May 14, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that Sun Pharmaceutical Industries, Inc. and MiCal Pharmaceuticals LLC initiated patent litigations on May 9 and 10, 2018, in the U.S. District Court for the District of Delaware and in th
Read more →PRGOPerrigo Expects Complete Response Letter On Generic Version Of ProAir®
DUBLIN, May 11, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it expects to receive a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its Abbreviated New Drug Application (ANDA) for its generic version of ProA
Read more →PRGOPerrigo Company plc Reports First Quarter 2018 Financial Results
DUBLIN, May 8, 2018 /PRNewswire/ -- Realized first quarter 2018 GAAP ("reported") net sales of $1.2 billion, reported net income of $81 million compared to $72 million last year, an increase of 12.9%, and reported diluted earnings per share ("EPS") of $0.57 compared to $0.50 las
Read more →PRGOPERRIGO COMPANY PLC REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS Realized first quarter 2018 GAAP ("reported") net sales of $1.2 billion , reported net income of $81 million compared to $72 million
PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS Dublin, Ireland - May 8, 2018 - Perrigo Company plc (NYSE; TASE: PRGO) today announced financial results for the first quarter ended March 31, 2018. Additional first quarter reported results: Reported operating ma
Read more →PRGOPerrigo To Release First Quarter Calendar Year 2018 Financial Results On May 8, 2018
DUBLIN, April 24, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its first quarter calendar year 2018 financial results on Tuesday, May 8, 2018. The Company will host a conference call beginning at 8:30 a.m. (EDT). The conference
Read more →PRGOPerrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn
DUBLIN, April 11, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) and its partner Dexcel Pharma Technologies, Ltd., today announced the launch of store brand Omeprazole Delayed Release Orally Disintegrating Tablets 20mg (Omeprazole ODT), an over-the-counter (OTC) medi
Read more →PRGOPERRIGO COMPANY PLC REPORTS FOURTH QUARTER & CALENDAR YEAR 2017 FINANCIAL RESULTS Fourth Quarter Realized fourth quarter 2017 GAAP ("reported") net sales of $1.3 billion , reported net income of $73
PERRIGO COMPANY PLC REPORTS FOURTH QUARTER & CALENDAR YEAR 2017 FINANCIAL RESULTS Dublin, Ireland - March 1, 2018 - Perrigo Company plc (NYSE; TASE: PRGO) today announced results for the fourth quarter and calendar year ended December 31, 2017. Additional fourth quarter reporte
Read more →PRGOPerrigo Company plc Reports Fourth Quarter & Calendar Year 2017 Financial Results
DUBLIN, March 1, 2018 /PRNewswire/ -- Realized fourth quarter 2017 GAAP ("reported") net sales of $1.3 billion, reported net income of $73 million and reported diluted earnings per share ("EPS") of $0.52 compared to a loss per share of $9.48 last year Delivered fourth quarter a
Read more →PRGOPerrigo Files Form 10-K With SEC; Will Host Fourth Quarter And Calendar Year 2017 Financial Results Conference Call On March 2, 2018
DUBLIN, March 1, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission and released its fourth quarter and calendar year 20
Read more →PRGOPERRIGO COMPANY PLC REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, prev
PERRIGO COMPANY PLC REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, previously scheduled for Tuesday, February 27, 2018 Select Preliminary Unaudited Cal
Read more →PRGOPerrigo Company plc Reports Select Preliminary Unaudited Calendar Year 2017 Financial Results
DUBLIN, Feb. 27, 2018 /PRNewswire/ -- Select Preliminary Unaudited Calendar Year 2017 Results Delivered strong calendar year 2017 GAAP ("reported") and adjusted net sales at the high end of previous guidance range and operating cash flow above previous company guidance Generat
Read more →PRGOPerrigo Appoints Ronald L. Winowiecki as Chief Financial Officer
DUBLIN, Feb. 20, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced that Ronald L. Winowiecki has been appointed Chief Financial Officer. Winowiecki has served as Acting CFO since Febr
Read more →PRGOPerrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%
DUBLIN, Feb. 20, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Finacea® Foam (azelaic acid foam, 15%). Following no
Read more →PRGOPerrigo To Release Fourth Quarter And Calendar Year 2017 Financial Results On February 27, 2018
DUBLIN, Feb. 8, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2017 financial results on Tuesday, February 27, 2018. The Company will also host a conference call beginning at 9:30 a.m. (EST).
Read more →PRGOPerrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra® Cream, 1%
DUBLIN, Jan. 30, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Soolantra® (ivermectin) cream, 1%. Perrigo previously announced a patent litigatio
Read more →PRGOPerrigo Announces Tentative FDA Approval For The Generic Version Of Onexton® Gel
DUBLIN, Jan. 26, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%). Perrigo prev
Read more →PRGOPerrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream
DUBLIN, Jan. 24, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for the generic version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%). This product will be marketed by
Read more →PRGOPerrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo® Gel
DUBLIN, Jan. 24, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration and has launched an AB rated generic version of Epiduo® (adapalene and benzoyl peroxide) Gel, 0.1%/2.5%. Epiduo®
Read more →PRGOPerrigo Appoints Uwe Röhrhoff As President & Chief Executive Officer
DUBLIN, Jan. 8, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of Uwe Röhrhoff as Chief Executive Officer, effective January 15, 2018, following the retirement of J
Read more →PRGOPerrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa® Ophthalmic Solution 0.07%
DUBLIN, Jan. 3, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Prolensa® (bromfenac ophthalmic solution) 0.07%. Perrigo previously settled litigat
Read more →PRGOPerrigo Announces the Launch of an AB Rated Generic Version of Mycolog® II Cream
DUBLIN, Nov. 27, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB rated generic version of Mycolog® II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/gram). Mycolog® II Cream is indicated for the
Read more →PRGOPerrigo Company Completes Divestiture Of API Business For $110 Million
DUBLIN, Nov. 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its Active Pharmaceutical Ingredient (API) business based in Israel to SK Capital for $110 million. Perrigo's CEO John T. He
Read more →PRGOPerrigo Company to Present at the Stifel 2017 Healthcare Conference
DUBLIN, Nov. 10, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Stifel Healthcare Conference at 8:45 AM EST on Tuesday, November 14, 2017. Interested parties can acces
Read more →PRGOPERRIGO COMPANY PLC REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Delivered third quarter 2017 GAAP ("reported") net sales of $1.2 billion , reported net income of $45 million and reported diluted ea
PERRIGO COMPANY PLC REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Dublin, Ireland - November 9, 2017 - Perrigo Company plc (NYSE; TASE: PRGO) today announced results for the third quarter ended September 30, 2017. Additional GAAP reported results: Reported net sales were lower i
Read more →PRGOPerrigo Company plc Reports Third Quarter 2017 Financial Results
DUBLIN, Nov. 9, 2017 /PRNewswire/ -- Delivered third quarter 2017 GAAP ("reported") net sales of $1.2 billion, reported net income of $45 million and reported diluted earnings per share ("EPS") of $0.31 compared to a loss per share of $11.10 last year Delivered third quarter ad
Read more →PRGOPerrigo Announces Tentative FDA Approval for a First-to-File Generic Version of Picato® Gel 0.05%
DUBLIN, Nov. 2, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol mebutate) 0.05%. The submission date of Perrigo's Abbr
Read more →PRGOPerrigo Company plc Announces Quarterly Dividend
DUBLIN, Nov. 2, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on December 19, 2017 to shareholders of record on December 1, 2017. Perrigo Company plc, a leading gl
Read more →PRGOPerrigo To Release Third Quarter 2017 Financial Results On November 9, 2017
DUBLIN, Oct. 26, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter 2017 financial results on Thursday, November 9, 2017. The Company will also host a conference call beginning at 8:00 a.m. (EST). The conference cal
Read more →PRGOPerrigo Announces Patent Litigation Settlement for the Generic Version of Onexton® Gel
DUBLIN, Oct. 26, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Onexton® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) brought by Valeant Pharmaceuticals North America LLC and D
Read more →PRGOPerrigo Announces Tentative FDA Approval For A First-To-File Generic Version Of Picato® Gel .015%
DUBLIN, Oct. 24, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Picato® Gel (ingenol mebutate) 0.015%. The submission date of Perrigo's Ab
Read more →PRGOPerrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent Of Nexium® 24HR Capsules
DUBLIN, Sept. 27, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has initiated shipments to retail customers of the first-to-market over-the-counter ("OTC") store brand equivalent of Nexium® 24HR (esomeprazole magnesium) capsules. This product is p
Read more →PRGOPerrigo Announces FDA Final Approval For Its AB Rated Generic Version Of Exalgo® 32mg Extended Release Tablets
DUBLIN, Sept. 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Exalgo® 32mg extended release tablets (hydromorpho
Read more →PRGOPerrigo Announces Tentative FDA Approval For The Generic Version Of Acanya® Gel
DUBLIN, Sept. 18, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya® (clindamycin phosphate and benzoyl peroxide) topical gel 1.2%/2.5%. Perri
Read more →PRGOPerrigo Company To Present At Upcoming Investor Conferences
DUBLIN, Aug. 30, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Wells Fargo Healthcare Conference at 4:10 PM EDT on Wednesday, September 6, 2017. The Company also anno
Read more →PRGOPerrigo Announces Final FDA Approval And Settlement For The Store Brand OTC Equivalent Of Nexium® 24HR Capsules
DUBLIN, Aug. 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug Administration for the store brand OTC equivalent of Nexium® 24HR (esomeprazole magnesium) capsules. The company also announc
Read more →PRGOPerrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog® II Cream
DUBLIN, Aug. 16, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Mycolog® II Cream (nystatin and triamcinolone aceto
Read more →PRGOPERRIGO COMPANY PLC REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS
PERRIGO COMPANY PLC REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Dublin, Ireland - August 10, 2017 - Perrigo Company plc (NYSE; TASE: PRGO) today announced results for the second quarter ended July 1, 2017. Additional GAAP reported results: Reported net sales were lower in the
Read more →PRGOPerrigo Company plc Reports Second Quarter 2017 Financial Results
DUBLIN, Aug. 10, 2017 /PRNewswire/ -- Delivered second quarter 2017 GAAP ("reported") net sales of $1.2 billion CHC Americas segment reported nets sales of $605 million compared to $630 million last year, lower by 4%; Adjusted net sales grew 3%, excluding $42 million from the U
Read more →PRGOPerrigo Announces Tentative FDA Approval For Generic Version Of Mirvaso® Gel
DUBLIN, Aug. 4, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Mirvaso® (brimonidine) topical gel 0.33%. Perrigo previously settled litigation wit
Read more →PRGOPerrigo Announces The Launch Of The AB Rated Generic Version Of Transderm Scop® 1.5 mg
DUBLIN, July 31, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) and its co-development partner Aveva Drug Delivery Systems, Inc., an Apotex Company, today announced the prescription pharmaceutical launch of scopolamine 1.5 mg transdermal system patch, the AB rated ge
Read more →PRGOPerrigo To Release Second Quarter 2017 Financial Results On August 10, 2017
DUBLIN, July 27, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter 2017 financial results on Thursday, August 10, 2017. The Company will conduct a conference call at 8:00 a.m. (EDT) hosted by Perrigo Chief Executiv
Read more →PRGOPerrigo Announces FDA Final Approval For Its AB Rated Generic Version Of DermOtic® Oil, 0.01% Ear Drops
DUBLIN, July 19, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing DermOtic® Oil, 0.01% Ear Drops (fluocinolone aceton
Read more →PRGOPerrigo Announces FDA Final Approval For Its First-To-File Ab Rated Generic Version Of Androgel® Topical Gel, 1.62% Packets
DUBLIN, July 17, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing AbbVie Inc.'s Androgel® Topical Gel, 1.62% packets
Read more →PRGOPerrigo Confirms Patent Challenge For Generic Version Of Soolantra® Cream, 1%
DUBLIN, July 17, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Soolantra® (ivermectin) cream, 1%. Follo
Read more →PRGOPerrigo Announces Settlement Of Generic Version Of Dymista® Nasal Spray Patent Litigation
DUBLIN, July 17, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Dymista® (azelastine hydrochloride and fluticasone propionate) nasal spray brought by Meda Pharmaceuticals Inc. and Cipla Ltd.
Read more →PRGOPerrigo Launches The Generic Version Of Axiron® Topical Solution
DUBLIN, July 5, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and Company's Axiron® Topical Solution, 30 mg/1.5 mL (CIII
Read more →PRGOPerrigo Company Retains Spencer Stuart for CEO Search
DUBLIN, June 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality Affordable Healthcare Products®", today announced that the Company's Board of Directors has retained Spencer Stuart, a leading global executive search and leadershi
Read more →PRGOPerrigo Announces the Launch of Generic Equivalents to Derma-Smoothe/FS® Scalp Oil and Body Oil
DUBLIN, June 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%) and Derma-Smoothe/FS® Body Oil (fluocinolone acet
Read more →PRGOPerrigo Announces the Launch of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution
DUBLIN, June 19, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched hydrocodone bitartrate and homatropine methylbromide oral solution. Hydrocodone bitartrate and homatropine methylbromide oral solution was formerly marketed under the trad
Read more →PRGOPerrigo Company plc Announces Pricing for its Cash Tender Offer
DUBLIN, June 14, 2017 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the reference yield and total consideration for each series of notes subject to the previously announced cash tender offer (the "Tender Offer") for up to a co
Read more →PRGOPerrigo Company plc Announces Early Tender Results for Cash Tender Offer DUBLIN
Perrigo Company plc Announces Early Tender Results for Cash Tender Offer DUBLIN, June 14, 2017 /PRNewswire/ Perrigo Company plc ( Perrigo or the Company ) (NYSE; TASE: PRGO) announced today the early tender results as of 5:00 p.m., New York City time, June 13, 2017 (the Early T
Read more →PRGOPerrigo Company To Present At The 17th Annual Oppenheimer Consumer Conference
DUBLIN, June 14, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Jeff Needham, Perrigo's Executive Vice President and President, Consumer Healthcare Americas, will present at the Oppenheimer 2017 Consumer Conference at 9:45 AM EST on Tuesday, June
Read more →PRGOPERRIGO ANNOUNCES FORTHCOMING RETIREMENT OF CEO JOHN HENDRICKSON Dublin, Ireland
PERRIGO ANNOUNCES FORTHCOMING RETIREMENT OF CEO JOHN HENDRICKSON Dublin, Ireland June 5, 2017 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products , today announced the forthcoming retirement of Chief Executive Officer John
Read more →PRGOPerrigo Company To Present At The Jefferies 2017 Healthcare Conference
DUBLIN, June 2, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo CEO John T. Hendrickson will present at the Jefferies 2017 Healthcare Conference at 3:00 PM EDT on Tuesday, June 6, 2017. Interested parties can access the presentation webcas
Read more →PRGOPerrigo Company plc Announces $1,400,000,000 Cash Tender Offer for Certain Notes DUBLIN
Perrigo Company plc Announces $1,400,000,000 Cash Tender Offer for Certain Notes DUBLIN, May 31, 2017 /PRNewswire/ Perrigo Company plc ( Perrigo or the Company ) (NYSE; TASE: PRGO) announced today that it and Perrigo Finance Unlimited Company, its wholly-owned finance subsidiar
Read more →PRGOPERRIGO COMPANY PLC FILES FIRST QUARTER 2017 FORM 10-Q AND REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS
PERRIGO COMPANY PLC FILES FIRST QUARTER 2017 FORM 10-Q AND REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS Dublin, Ireland - May 31, 2017 - Perrigo Company plc (NYSE; TASE: PRGO) today announced results for the first quarter ended April 1, 2017. Perrigo CEO John T. Hendrickson com
Read more →PRGOPerrigo To Conduct Conference Call On May 31, 2017 At 8:30 AM ET
DUBLIN, May 30, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Wednesday, May 31 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer, to discuss the Company's first quarter 2017 res
Read more →PRGOPerrigo Company plc Files First Quarter 2017 Form 10-Q And Reports First Quarter 2017 Financial Results
DUBLIN, May 30, 2017 /PRNewswire/ -- Delivered first quarter 2017 GAAP ("reported") net sales of $1.2 billion, led by consumer-facing businesses net sales of $958 million Realized first quarter reported net income of $72 million and reported earnings per share ("EPS") of $0.50
Read more →PRGOPERRIGO COMPANY PLC SELECTED CONSOLIDATED INFORMATION QUARTERS AND CALENDAR YEAR TO DATE 2016 (in millions) (unaudited) Three Months Ended Twelve Months Ended Consolidated
SELECTED CONSOLIDATED INFORMATION QUARTERS AND CALENDAR YEAR TO DATE 2016 Three Months Ended Twelve Months Ended Consolidated April 2, 2016 July 2, 2016 October 1, 2016 December 31, 2016 December 31, 2016 Net sales $ 1,347.3 $ 1,340.5 $ 1,261.6 $ 1,331.2 $ 5,280.6
Read more →PRGOPERRIGO FILES 2016 FORM 10-K WITH RESTATED FINANCIAL STATEMENTS; REPORTS FOURTH QUARTER AND CALENDAR YEAR 2016 FINANCIAL RESULTS; ANNOUNCES 2017 ANNUAL MEETING DATE Comprehensive Form 10-K reflects
PERRIGO FILES 2016 FORM 10-K WITH RESTATED FINANCIAL STATEMENTS; REPORTS FOURTH QUARTER AND CALENDAR YEAR 2016 FINANCIAL RESULTS; ANNOUNCES 2017 ANNUAL MEETING DATE 1) reported (GAAP) net sales range of $5.1 billion to $5.3 billion; adjusted (Non-GAAP) net sales range of $5.0 bi
Read more →PRGOPerrigo Files 2016 Form 10-K With Restated Financial Statements; Reports Fourth Quarter And Calendar Year 2016 Financial Results; Announces 2017 Annual Meeting Date
DUBLIN, May 22, 2017 /PRNewswire/ -- Comprehensive Form 10-K reflects accounting treatment of historical Tysabri® royalty stream as a financial asset No impact on net cash flows or previously closed sale of Tysabri® Revised previously reported 2016 guidance to reflect the new
Read more →PRGOPerrigo to Conduct Conference Call on May 23, 2017 at 8:30 AM ET
DUBLIN, May 22, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Tuesday, May 23 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer, to discuss the Company's fourth quarter and calen
Read more →PRGOPerrigo Announces Two New Independent Directors
DUBLIN, May 8, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the appointment of Rolf A. Classon and Adriana Karaboutis to the Company's Board of Directors. Pursuant to the agreement with Starboard Value LP ("Starboard") announced on February 7, 2017
Read more →PRGOPerrigo Discloses Investigation
DUBLIN, May 2, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that search warrants were executed at the Company's corporate offices associated with an ongoing investigation by the U.S. Department of Justice Antitrust Division related to drug pricing i
Read more →PRGOPERRIGO ANNOUNCES RESTATEMENT OF PREVIOUSLY ISSUED FORMS 10-K AND 10-Q FINANCIAL STATEMENTS; ANNOUNCES SELECT PRELIMINARY UNAUDITED FIRST QUARTER 2017 FINANCIAL RESULTS Tysabri historical royalty st
PERRIGO ANNOUNCES RESTATEMENT OF PREVIOUSLY ISSUED FORMS 10-K AND 10-Q FINANCIAL STATEMENTS; ANNOUNCES SELECT PRELIMINARY UNAUDITED FIRST QUARTER 2017 FINANCIAL RESULTS Dublin, Ireland - April 25, 2017 - Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affo
Read more →PRGOPerrigo Announces Restatement Of Previously Issued Forms 10-K And 10-Q Financial Statements; Announces Select Preliminary Unaudited First Quarter 2017 Financial Results
DUBLIN, April 25, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today announced that the Company's Board of Directors, after consultation with management and discussion with Ernst & Young LLP, the Comp
Read more →PRGOPerrigo Completes Divestiture Of Tysabri® Royalty Stream For Up To $2.85 Billion
DUBLIN, March 27, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has completed the divestiture of its rights to the royalty stream from global net sales of the multiple sclerosi
Read more →PRGOPerrigo Provides Update On 2016 Form 10-K Filing
DUBLIN, March 16, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "We continue to make progress with our independent auditor, Ernst & Young ("E&Y"), in addressing the technical accountin
Read more →PRGOPerrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women
DUBLIN, March 8, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the first-to-market launch of the over-the-counter ("OTC") store brand equivalent to Women's Rogaine® 5% minoxidil foam (minoxidil topical aerosol, 5% foam). First shipments of this new s
Read more →PRGOPerrigo Provides 2016 Form 10-K Update
DUBLIN, March 7, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "As previously discussed, in connection with a review for the announced sale of the Tysabri® royalty stream and evaluatio
Read more →PRGOPerrigo Announces FDA Final Approval For The Generic Version Of Axiron® Topical Solution, 30 mg/1.5 mL
DUBLIN, March 1, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application referencing Eli Lilly and Company's Axiron® Topical Solution, 30 mg/1.5
Read more →PRGOPerrigo Company plc Reports Select Preliminary Unaudited Calendar Year 2016 Financial Results And Initial Calendar Year 2017 Guidance
DUBLIN, Feb. 27, 2017 /PRNewswire/ -- Delivered preliminary unaudited calendar year 2016 record reported net sales of $5.6 billion and adjusted net sales of $5.5 billion Unaudited calendar year 2016 preliminary reported loss per diluted share in a range of $(28.85) - $(29.00) p
Read more →PRGOPerrigo Signs Agreement To Divest Tysabri® Royalty Stream For Up To $2.85 Billion
DUBLIN, Feb. 27, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced it has signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the mul
Read more →PRGODublin, Ireland - February 27, 2017 - Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products , today announced select prelimina
PERRIGO COMPANY PLC REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2016 FINANCIAL RESULTS AND INITIAL CALENDAR YEAR 2017 GUIDANCE Dublin, Ireland - February 27, 2017 - Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products
Read more →PRGOPerrigo Announces Leadership Changes
DUBLIN, Feb. 27, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced that Ron Winowiecki, Senior Vice President, Business Finance, has been appointed acting Chief Financial Officer, eff
Read more →PRGOPerrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution
DUBLIN, Feb. 17, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL. Hydrocodon
Read more →PRGOPerrigo To Release Fourth Quarter And Calendar Year 2016 Results On February 27, 2017
DUBLIN, Feb. 14, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release financial results for its fourth quarter and calendar year 2016 on Monday, February 27, 2017 at approximately 4:00 p.m. (ET). The Company will conduct a conference ca
Read more →PRGOPerrigo Announces Agreement With Starboard
DUBLIN, Feb. 7, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has entered into an agreement with Starboard Value LP ("Starboard"), which owns approximately 6.7 percent of Perrigo's shares, regarding the membership and composition of the Perri
Read more →PRGOPerrigo Confirms Patent Challenge For Generic Version Of Onexton® Gel
DUBLIN, Feb. 7, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for clindamycin, benzoyl peroxide topical gel, the generic version of Onexton® gel (
Read more →PRGOPerrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort® Spray, 0.25%
DUBLIN, Jan. 24, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received U.S. Food and Drug Administration approval for its first-to-file Abbreviated New Drug Application referencing Taro Pharmaceuticals USA Inc.'s Topicort® Spray, 0.25% (desox
Read more →PRGOPerrigo Updates Segment Reporting Structure
DUBLIN, Jan. 10, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has changed its reporting segments to better align with the Company's organizational structure. Beginning with the fourth quarter of calendar year 2016, the Company's new reportin
Read more →PRGOPERRIGO COMPANY PLC SELECTED SEGMENT INFORMATION QUARTERS AND CALENDAR YEAR TO DATE 2016 (in millions) (unaudited) Three Months Ended Nine Months Ended Consumer Healthcare Americas
SELECTED SEGMENT INFORMATION QUARTERS AND CALENDAR YEAR TO DATE 2016 Three Months Ended Nine Months Ended Consumer Healthcare Americas April 2, 2016 July 2, 2016 October 1, 2016 October 1, 2016 Net sales $ 639.1 $ 629.9 $ 611.2 $ 1,880.2 Gross profit $ 199.0 $ 216.
Read more →PRGOPerrigo Announces FDA Approvals For The Store Brand OTC Equivalents To Nicorette® White Ice Mint® Gum
DUBLIN, Dec. 20, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received approvals from the U.S. Food and Drug Administration for Abbreviated New Drug Applications referencing GlaxoSmithKline's Nicorette® White Ice Mint® Gum (nicotine polacrile
Read more →PRGOPerrigo Announces Portfolio Review Developments And Intention To Restructure Branded Consumer Healthcare
DUBLIN, Dec. 8, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced its intention to restructure the Branded Consumer Healthcare's ("BCH") Omega Pharma Belgium business (which includes Omega Pharma Belgium NV, Etixx NV and Biover NV), located in Nazareth,
Read more →PRGOPerrigo Company Plc to Review Strategic Alternatives for Tysabri® Royalty Stream
DUBLIN, Nov. 10, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug Tysabr
Read more →PRGOPerrigo Company plc Announces Appointment of Two New Independent Directors to Board
DUBLIN, Nov. 10, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced the appointment of independent Directors Geoffrey M. Parker and Theodore R. Samuels to its Board of Directors, further enhancing its corporate governance and the depth and breadth of expe
Read more →PRGOPerrigo Company plc Reports Third Quarter 2016 Financial Results
DUBLIN, Nov. 10, 2016 /PRNewswire/ -- Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered third quarter reported net loss of $1.3 billion
Read more →PRGOPERRIGO COMPANY PLC REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS
PERRIGO COMPANY PLC REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS The Company expects calendar year 2016 reported loss per diluted share to be in the range of $9.04 to $9.34 (compared to a loss of $0.23 in calendar year 2015) and continues to expect calendar year adjusted earning
Read more →PRGOPerrigo Company plc to Release Third Quarter Calendar Year 2016 Results on November 10, 2016
DUBLIN, Oct. 26, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its third quarter calendar year 2016 on Thursday, November 10, 2016 at approximately 6:30 a.m. (ET). The Company will conduct a conference call
Read more →PRGOPerrigo Invests In Tarex® Patented Technology, As A Key Investment In The Fight Against Methamphetamine Drug Abuse
DUBLIN, Sept. 27, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine ("meth") blocking technology and the distribution rights of Zephrex-D® (pseudoephedrine
Read more →PRGOPerrigo Acknowledges Receipt Of Letter From Starboard Value LP
DUBLIN, Sept. 12, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today acknowledged receipt of a letter from Starboard Value LP, a Perrigo shareholder. Perrigo will review the letter carefully and looks forward to a constructive and productive dialogue with Starboar
Read more →PRGOPerrigo Company to Present at Upcoming Investor Conferences
DUBLIN, Sept. 7, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the Morgan Stanley Global Healthcare Conference at 11:05 AM EDT on Monday, September 12, 2016 at the Grand Hyatt i
Read more →PRGOPerrigo Announces Tentative FDA Approval For Generic Version Of Epiduo® Gel
DUBLIN, Sept. 1, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo® Gel (adapalene and benzoyl peroxide 0.1%/2.5%). Epiduo® Gel (adapalene an
Read more →PRGOPerrigo Announces Tentative FDA Approval For Generic Version Of Suprep® Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso® Gel
DUBLIN, Aug. 23, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution
Read more →PRGOPerrigo to Acquire U.S. Distributor of Healthcare & Consumer Goods Products, Geiss, Destin & Dunn
DUBLIN, Aug. 17, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has agreed to acquire Peachtree City, Georgia-based, Geiss, Destin & Dunn, Inc. ("GDD"), a small national distributor of over-the-counter healthcare and consumer goods products to
Read more →PRGOPerrigo Company plc Reports Second Quarter 2016 Financial Results
DUBLIN, Aug. 10, 2016 /PRNewswire/ -- Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion, excluding sales of $44 million from held-for-sale businesses* Delivered second quarter reported net income of $194 milli
Read more →PRGOPERRIGO COMPANY PLC REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion , excluding s
PERRIGO COMPANY PLC REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS Primarily due to revised expectations for the Rx segment, the Company now expects calendar year 2016 reported earnings per diluted share in the range of $0.26 to $0.56 (compared to a loss of $0.23 in calendar year
Read more →PRGOPerrigo Completes The Divestiture Of Its Vitamins, Minerals & Supplements Business To IVC
DUBLIN, Aug. 8, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin Corporation (IVC). Perrigo Company plc is a
Read more →PRGOPerrigo Company plc To Release Second Quarter Calendar Year 2016 Results On August 10, 2016
DUBLIN, July 27, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2016 on Wednesday, August 10th, 2016 at approximately 6:00 a.m. (ET). The Company will conduct a conference cal
Read more →PRGOPerrigo Announces Leadership Change in Rx Pharmaceuticals Segment
DUBLIN, July 20, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the departure of Douglas Boothe, Executive Vice President and General Manager, Rx Pharm
Read more →PRGOPerrigo Announces FDA Final Approval And Launch Of The Store Brand Equivalent To Zegerid OTC® Capsules
DUBLIN, July 18, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that the U.S. Food and Drug Administration has approved the company's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg. This approval will initiate the first store brand l
Read more →PRGOPERRIGO 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Perrigo Company plc - PRGO
NEW ORLEANS, July 15, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until July 18, 2016 to file lead plaintiff applicatio
Read more →PRGOPerrigo Announces FDA Clearance And Launch Of Non-GMO* Infant Formulas For The U.S. Store Brand Market
DUBLIN, June 21, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), today announced it has received final U.S. Food and Drug Administration ("FDA") clearance for three milk-based, store brand non-GMO infant formulas. Shipments to retail customers have already commenced.
Read more →PRGOPerrigo Divests Vitamins, Minerals & Supplements Business To IVC
DUBLIN, June 20, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has reached a definitive agreement to sell its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin Corporation (IVC). The transaction is subject to custo
Read more →PRGOPerrigo Company to Present at the Oppenheimer 16th Annual Consumer Conference
DUBLIN, Ireland, June 16, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the 16th Annual Oppenheimer Consumer Conference at 9:05 AM EDT on Tuesday, June 21, 2016 at the Four Seas
Read more →PRGOPerrigo Announces FDA Approval Of The Generic Version Of Ofirmev® Acetaminophen Injection
DUBLIN, June 16, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Mallinckrodt Pharmaceuticals' Ofirmev® (acetaminophen) injection 1000 mg/100 mL. As pr
Read more →PRGOPerrigo Confirms First To File Patent Challenge For Generic Version Of Picato® Gel (0.015% And 0.05%)
DUBLIN, June 13, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced that it has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for ingenol mebutate gel (0.015% and 0.05%), the generic versions of Picato® gel (0.
Read more →PRGOPERRIGO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Perrigo Company plc - PRGO
NEW ORLEANS, LA--(Marketwired - June 03, 2016) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 18, 2016 to file lead plaintiff applications in a securities class action l
Read more →PRGOPerrigo Announces FDA Approval And Launch Of The Store Brand Equivalent To Flonase®
DUBLIN, May 31, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) and its partner West-Ward Pharmaceuticals Corp. today announced the U.S. Food and Drug Administration has approved, and that Perrigo has launched, fluticasone propionate nasal spray USP, 50 mcg per spray,
Read more →PRGOPERRIGO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Perrigo Company plc - PRGO
NEW ORLEANS, May 20, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 18, 2016 to file lead plaintiff applications in a securities class action lawsu
Read more →PRGOPerrigo Company to Present at the UBS Global Healthcare Conference
DUBLIN, May 18, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the UBS Global Healthcare Conference at 1:30 PM EDT on Tuesday, May 24, 2016 at the Grand Hyatt in New York City, N
Read more →PRGOCorrecting and Replacing GAAP Net Loss on Consolidated Statement of Operations for First Quarter 2016
DUBLIN, May 16, 2016 /PRNewswire/ -- The full corrected release reads as follows: PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Delivered record first quarter adjusted net sales of $1.34 billion excluding VMS sales of $47 million, an increase of 32% compared
Read more →PRGOPerrigo Company plc Reports First Quarter 2016 Financial Results
DUBLIN, May 12, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced results for the first quarter ended April 2, 2016. Perrigo's CEO John T. Hendrickson commented, "It is an honor and privilege to be the tenth and newest CEO of Perrigo and I see a bright
Read more →PRGOPERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Delivered record first quarter adjusted net sales of $1.34 billion excluding VMS sales of $47 million, an increase of 32% compared to
PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Dublin, Ireland - May 12, 2016 - Perrigo Company plc (NYSE: PRGO; TASE) today announced results for the first quarter ended April 2, 2016. Perrigo's CEO John T. Hendrickson commented, "It is an honor and privilege
Read more →PRGOCORRECTING AND REPLACING GAAP NET LOSS ON CONSOLIDATED STATEMENT OF OPERATIONS FOR FIRST QUARTER 2016 No changes to adjusted results or adjusted guidance from original earnings release issued on
CORRECTING AND REPLACING GAAP NET LOSS ON CONSOLIDATED STATEMENT OF OPERATIONS FOR FIRST QUARTER 2016 The full corrected release reads as follows: PERRIGO COMPANY PLC REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Dublin, Ireland - May 16, 2016 - Perrigo Company plc (NYSE: PRGO;
Read more →PRGOPerrigo Company plc To Release First Quarter Calendar Year 2016 Results On May 12, 2016
DUBLIN, May 11, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its first quarter calendar year 2016 on Thursday, May 12, 2016 at approximately 6:00 a.m. (ET). The Company will conduct a conference call at 8:0
Read more →PRGOPerrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin® Pump Topical Gel
DUBLIN, May 2, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Valeant Pharmaceutical International, Inc.'s BenzaClin® Pump Topical Gel. Shipments to cu
Read more →PRGOPerrigo Expands the Responsibilities of Sharon Kochan, Perrigo
DUBLIN, April 28, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced that Mr. Sharon Kochan, Perrigo's Executive Vice President and General Manager, Intern
Read more →PRGOPerrigo Appoints John T. Hendrickson as Chief Executive Officer, Provides Preliminary First Quarter 2016 Selected Financial Results, and Updates Full Year 2016 Guidance
DUBLIN, April 25, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products®, today announced the appointment of John T. Hendrickson as Chief Executive Officer, effective immediate
Read more →PRGOPerrigo Responds To Market Rumors
DUBLIN, April 22, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today released the following statement regarding recent media coverage concerning Chairman and CEO Joseph C. Papa: "We are aware of the speculation regarding our Chairman and CEO Joseph Papa. As is our
Read more →PRGOPerrigo Announces First-to-Market Launch of the OTC Store Brand Equivalent to Glucerna® Aseptic Adult Nutritional Shake
DUBLIN, April 12, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced the first-to-market launch of the over-the-counter (OTC) store brand equivalent to Glucerna® aseptic adult nutritional shake for people with diabetes. First shipments of this new store b
Read more →PRGOPerrigo Company To Present At The Barclays Global Healthcare Conference
DUBLIN, March 10, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the Barclays Global Healthcare Conference at 10:15 AM EST on Tuesday, March 15, 2016 at the Loews Miami Beach Hotel in Miami Beach,
Read more →PRGOPerrigo Company plc Announces The Closing Of A Senior Notes Offering By Its Finance Subsidiary, Perrigo Finance Unlimited Company
DUBLIN, March 10, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of the previously announced registered public offering by Perrigo Financ
Read more →PRGOPERRIGO COMPANY PLC ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY Dublin, Ireland (
PERRIGO COMPANY PLC ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY Dublin, Ireland (March 8, 2016) Perrigo Company plc ( Perrigo or the Company ) (NYSE: PRGO; TASE), a leading global provider of Quality Affordable
Read more →PRGOPERRIGO COMPANY PLC ANNOUNCES PROPOSED PUBLIC OFFERING OF SENIOR NOTES OF ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY Dublin, Ireland (
PERRIGO COMPANY PLC ANNOUNCES PROPOSED PUBLIC OFFERING OF SENIOR NOTES OF ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY Dublin, Ireland (March 7, 2016) Perrigo Company plc ( Perrigo or the Company ) (NYSE: PRGO; TASE), a leading global provider of Quality Affordabl
Read more →PRGOPerrigo Company To Present At The RBC Capital Markets Global Healthcare Conference
DUBLIN, Feb. 23, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the RBC Capital Markets Global Healthcare Conference at 8:00 AM EST on Wednesday, February 24, 2016 at the New York Palace Hotel in
Read more →PRGOPerrigo Furthers Commitment to Ireland
DUBLIN, Feb. 19, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), announced that a number of key public facing corporate functions will be relocated to Ireland as part of the Company's focused international growth strategy and global expansion. This announ
Read more →PRGOPERRIGO COMPANY PLC REPORTS RECORD FOURTH QUARTER & CALENDAR YEAR NET SALES AND ADJUSTED NET INCOME Delivered record calendar year 2015 net sales of $5.35 billion , an increase of 28% compared to th
PERRIGO COMPANY PLC REPORTS RECORD FOURTH QUARTER & CALENDAR YEAR NET SALES AND ADJUSTED NET INCOME Dublin, Ireland - February 18, 2016 - Perrigo Company plc (NYSE: PRGO; TASE) today announced results for the fourth quarter and calendar year ended December 31, 2015. Perrigo's C
Read more →PRGOPerrigo Company plc Reports Record Fourth Quarter & Calendar Year Net Sales And Adjusted Net Income
DUBLIN, Feb. 18, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced results for the fourth quarter and calendar year ended December 31, 2015. Perrigo's Chairman and CEO Joseph C. Papa commented, "The team delivered record performance in the face of a bus
Read more →PRGOPerrigo Company plc To Announce Calendar Year & Fourth Quarter 2015 Earnings Results On February 18, 2016
DUBLIN, Feb. 11, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will announce financial results for its calendar year and fourth quarter 2015 on Thursday, February 18, 2016 at approximately 6:00 a.m. (ET). The Company will conduct a conference
Read more →PRGOPerrigo Completes The Acquisition Of Generic Retin-A® Portfolio, Further Enhancing Rx "Extended Topicals" Strategy
DUBLIN, Jan. 25, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A® (tretinoin) from Matawan Pharmaceuticals, LLC. Perr
Read more →PRGOPERRIGO COMPANY PLC INCREASES 2016 FULL-YEAR ADJUSTED EARNINGS PER SHARE GUIDANCE Expects full-year 2016 adjusted earnings per diluted share to be in a range of $9.50 to $10.10, an increase of 24% t
PERRIGO COMPANY PLC INCREASES 2016 FULL-YEAR ADJUSTED EARNINGS PER SHARE GUIDANCE DUBLIN, Ireland - January 11, 2016 - Perrigo Company plc (NYSE: PRGO; TASE) today increased full-year 2016 adjusted earnings per diluted share guidance to be in a range of $9.50 to $10.10, up from
Read more →PRGOPerrigo Initiates Voluntary Product Recall In The U.S. Of Children
DUBLIN, Jan. 11, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that, following the recent recall of certain dosing cups by its supplier, it has initiated a voluntary product recall in the US to the retail level of 2 batches of its children's guaifene
Read more →PRGOPerrigo Company plc Increases 2016 Full-Year Adjusted Earnings Per Share Guidance
DUBLIN, Jan. 11, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today increased full-year 2016 adjusted earnings per diluted share guidance to be in a range of $9.50 to $10.10, up from the Company's October 22, 2015 guidance of $9.30 per diluted share. This increase
Read more →PRGOAllergan And Perrigo Announce First-To-Market Launch Of Store Brand Equivalent To Mucinex® D 600mg ER Tablets
DUBLIN, Jan. 4, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced the launch of combination guaifenesin 600mg and pseudoephedrine HCl 60mg extended-release tablets to retail and wholesale customers. First shipments of t
Read more →PRGOPerrigo Acquires Generic Retin-A® Portfolio, Furthering Rx "Extended Topicals" Strategy
DUBLIN, Dec. 17, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it will acquire a portfolio of generic dosage forms and strengths of Retin-A® (tretinoin) from Matawan Pharmaceuticals, LLC. Perrigo was the authorized generic distributo
Read more →PRGOPerrigo Furthers Rx "Extended Topicals" Strategy With The Acquisition Of Leading Gastrointestinal Product Entocort®
DUBLIN, Nov. 23, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it will acquire Entocort® (budesonide) capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals within the U.S. from AstraZeneca plc for $380 m
Read more →PRGOPerrigo Shareholders Convincingly Reject Mylan
DUBLIN, Nov. 13, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today responded to the news that holders of a majority of its shares rejected Mylan's hostile tender offer, thereby expressing confidence in Perrigo's long-term strategy, visio
Read more →PRGOPerrigo Reaffirms Views on Mylan
DUBLIN, Nov. 10, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) issued the following response to Mylan's press release. Mylan is resorting to desperate tactics on the eve of its tender offer deadline, having failed to persuade our long-ter
Read more →PRGOPerrigo Announces FDA Approval Of The AB Rated Generic Version Of KlorCon® Extended-Release Tablets
DUBLIN, Nov. 10, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration ("FDA") approval for the generic version of KlorCon® extended-release tablets (600 mg and 7
Read more →PRGOPerrigo Issues Shareholder Letter
DUBLIN, Nov. 9, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today issued the following shareholder letter: CORPORATE GOVERNANCE, MYLAN STYLE: A QUESTION OF TRUST Dear Perrigo Shareholder, At Perrigo transparency and openness with our
Read more →PRGOPerrigo Responds to Misleading Statements
DUBLIN, Nov. 9, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today responded to misleading statements regarding Marc Coucke, Perrigo Board member as well as Executive Committee member. In response, Mr. Coucke comments, "I believe that My
Read more →PRGOPerrigo Company To Present At The 24th Annual Credit Suisse Healthcare Conference
DUBLIN, Nov. 3, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 24th Annual Credit Suisse Healthcare Conference at 1:00 PM MST (3:00 PM EST) on Tuesday, November 10, 2015 at The Phoenicia
Read more →PRGOPerrigo Comments On Mylan
DUBLIN, Oct. 30, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today commented on the presentation given by Mylan N.V. ("Mylan") (NASDAQ: MYL) in connection with the announcement of its third quarter 2015 earnings results. Perrigo continues to strongly r
Read more →PRGOPerrigo Taking Actions To Deliver Shareholder Value Far Superior To Mylan Offer
DUBLIN, Oct. 22, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today announced it is taking actions to drive substantial profit growth in 2016 and beyond. In total, the actions are expected to add incremental benefits of $175 million when the full run ra
Read more →PRGOPerrigo Company plc Reports Record Third Quarter Highlighted By 10% Organic Net Sales Growth
DUBLIN, Oct. 22, 2015 /PRNewswire/ -- Third Quarter Calendar Year 2015* Highlights: Delivered record third quarter net sales of $1.34 billion, comprised of $977 million from consumer-facing businesses Grew net sales by 41%, highlighted by organic net sales of $95 million, an i
Read more →PRGOPerrigo Company plc To Release Third Quarter Calendar Year 2015 Results On October 22, 2015
DUBLIN, Oct. 19, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its third quarter calendar year 2015 on Thursday, October 22, 2015 at approximately 6:00 a.m. (ET). The Company will conduct a conference call a
Read more →PRGOPerrigo, Hain Celestial And Hutchison China MediTech Bring Earth
DUBLIN, Oct. 8, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), announced today that The Hain Celestial Group, Inc. (Nasdaq: HAIN) through its Earth's Best® brand, has begun to sell organic infant formula in Hong Kong and China, through Hutchison Hain Organic Holding
Read more →PRGOPerrigo and Flamel Enter Into Exclusive Licensing Agreement for LiquiTime® Extended Release Suspension Technology in the U.S. OTC Market
DUBLIN, Oct. 5, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) and Flamel Technologies (NASDAQ: FLML) announced today that they have entered into an exclusive licensing agreement for LiquiTime® extended release suspension. The technology will be utilized in the devel
Read more →PRGOPerrigo Announces FDA Approval and Launch of the AB Rated Generic Version of BenzaClin® Topical Gel
DUBLIN, Sept. 22, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration ("FDA") approval for the generic version of Valeant Pharmaceutical International, Inc.'s B
Read more →PRGOPerrigo Board Unanimously Rejects Mylan
DUBLIN, Sept. 17, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today announced that its Board of Directors has reviewed Mylan's unsolicited tender offer to acquire all of the outstanding shares of Perrigo and, in consultation with its financial and lega
Read more →PRGOPerrigo Announcement Regarding Unsolicited Offer From Mylan N.V.
DUBLIN, Sept. 14, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today confirmed that Mylan N.V. ("Mylan") (NASDAQ: MYL) has commenced an unsolicited exchange offer to acquire all of the issued and to be issued ordinary shares of Perrigo. Shareholders are
Read more →PRGOPerrigo Responds to Misleading Letter from Mylan Executive Chairman
DUBLIN, Sept. 10, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today responded to Mylan N.V.'s ("Mylan") (NASDAQ: MYL) letter to Perrigo dated September 8th, 2015. Perrigo Chairman, President and CEO Joseph C. Papa sent the following letter to Mylan Ex
Read more →PRGOPerrigo Company To Present At The Morgan Stanley 2015 Global Healthcare Conference
DUBLIN, Sept. 10, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Morgan Stanley 2015 Global Healthcare Conference at 12:55 PM EDT on Thursday, September 17, 2015 at the Grand
Read more →PRGOPerrigo Acquires Leading U.S. Scar Management Brand ScarAway®
DUBLIN, Aug. 31, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it has acquired ScarAway®, a leading U.S. OTC scar management brand, from Enaltus, LLC. The brand is expected to generate approximately $10 million in full, calendar year
Read more →PRGOPerrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK
DUBLIN, Aug. 28, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today announced that it has completed the acquisition of leading OTC brands from GSK in an all cash transaction valued at €200 million. The transaction is a clear demonstration of Perrigo's u
Read more →PRGOPerrigo Confident Its Shareholders Will Reject Mylan
DUBLIN, Aug. 28, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today commented on the Mylan N.V. ("Mylan") (NASDAQ: MYL) shareholder vote regarding its planned unsolicited offer to acquire Perrigo. "Our views of Mylan's offer to Perrigo shareholders hav
Read more →PRGOPerrigo Company plc To Release Second Quarter Calendar Year 2015 Results On August 5, 2015
DUBLIN, July 24, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter calendar year 2015 on Wednesday, August 5, 2015 at approximately 8:00 a.m. (ET). The Company will conduct a conference call a
Read more →PRGOPerrigo To Acquire Leading German Dietary Supplement Brand Yokebe
DUBLIN, July 22, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today announced that it has entered into an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is expected to generate approximatel
Read more →PRGOPerrigo To Acquire Portfolio Of Leading OTC Brands From GSK
DUBLIN, June 2, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today announced that it has entered into an agreement to acquire a portfolio of well-established over-the-counter ("OTC") brands from GlaxoSmithKline Consumer Healthcare ("GSK"), in connection
Read more →PRGOPerrigo Company To Present At The Jefferies 2015 Healthcare Conference
DUBLIN, May 27, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Jefferies 2015 Healthcare Conference at 4:30 PM EDT on Tuesday, June 2, 2015 at the Grand Hyatt Hotel in New Yor
Read more →PRGOPerrigo Company To Present At The UBS Global Healthcare Conference
DUBLIN, May 12, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the 2015 UBS Global Healthcare Conference at 11:30AM EST on Monday, May 18, 2015 at the Sheraton New York Times Squa
Read more →PRGOPerrigo Company To Present At Upcoming Healthcare Conferences
DUBLIN, April 30, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the 2015 Deutsche Bank 40th Annual Healthcare Conference at 11:20AM EDT on Wednesday, May 6, 2015 at the InterCont
Read more →PRGOPerrigo Rejects Latest Mylan Unsolicited Offer
DUBLIN, April 29, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today announced its rejection of the revised unsolicited offer from Mylan NV ("Mylan") (NASDAQ: MYL) to acquire all of the outstanding shares of Perrigo for $75.00 per share in cash and 2.3
Read more →PRGOPerrigo Rejects Mylan Unsolicited Offer
DUBLIN, April 24, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO, TASE) today announced its rejection of the unsolicited offer from Mylan NV ("Mylan") (NASDAQ: MYL) to acquire all of the outstanding shares of Perrigo for $60.00 per share in cash
Read more →PRGOPerrigo Company plc Reports Record Fiscal Third Quarter Net Sales, Adjusted Net Income, Adjusted Margins, And Operating Cash Flow
DUBLIN, April 21, 2015 /PRNewswire/ -- Third Quarter FY 2015 Highlights: Delivered record fiscal third quarter net sales of $1.05 billion. Excluding the effect of the pre-closing debt and equity issuances related to the Omega Pharma (Omega) acquisition, fiscal third quarter ad
Read more →PRGOPerrigo Board Unanimously Rejects Unsolicited Proposal From Mylan
DUBLIN, April 21, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) today announced that its Board of Directors has unanimously rejected the unsolicited Proposal (the "Proposal") from Mylan NV ("Mylan") (NASDAQ: MYL), disclosed April 8, 2015, to acquire all
Read more →PRGOPerrigo Announces FDA Approval and Upcoming Launch of the AB Therapeutic Equivalent to Exalgo®
DUBLIN, April 8, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application for hydromorphone HCI extended-release tablets 8 mg, 12 mg and
Read more →PRGOAnnouncement Regarding Possible Offer
DUBLIN, April 8, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE) notes the announcement made by Mylan NV ("Mylan") (NASDAQ: MYL). Perrigo confirms that it has received an unsolicited, indicative proposal from Mylan regarding a possible off
Read more →PRGOPerrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company
DUBLIN, March 30, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that it has completed the acquisition of Belgian-based Omega Pharma Invest N.V. ("Omega") in a cash and equity tr
Read more →PRGOPerrigo Company To Present At The 2015 RBC Global Healthcare Conference
DUBLIN, Feb. 17, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the 2015 RBC Global Healthcare Conference at 4:35PM EST on Tuesday, February 24, 2015 at the New York Palace Hotel
Read more →PRGOPerrigo Company plc Reports Record Second Quarter Revenue, Adjusted Net Income And Adjusted Margins
DUBLIN, Feb. 5, 2015 /PRNewswire/ -- Fiscal second quarter net sales increased to a second quarter record of $1.07 billion. Excluding the effect of the pre-closing debt and equity issuances related to the previously announced acquisition of Omega Pharma NV ("Omega"), fiscal sec
Read more →PRGOPerrigo Company plc To Release Second Quarter Fiscal Year 2015 Results On February 5, 2015 - Updating Call Time
DUBLIN, Jan. 29, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter fiscal year 2015 on Thursday, February 5, 2015 at approximately 7:30 a.m. (ET). The Company will conduct a conference call at
Read more →PRGOPerrigo Company plc To Release Second Quarter Fiscal Year 2015 Results On February 5, 2015
DUBLIN, Jan. 22, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter fiscal year 2015 on Thursday, February 5, 2015 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at
Read more →PRGOPerrigo Launches AB Therapeutic Equivalent Testosterone Gel 1.0%
DUBLIN, Jan. 12, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has launched its AB therapeutic equivalent testosterone gel 1.0%. The Food and Drug Administration (FDA) concluded previously that Perrigo's testosterone product is therapeuticall
Read more →PRGOPerrigo Partners With Ferrara Candy Company To Enter $625 Million Gummy Vitamins And Dietary Supplement Market
DUBLIN and OAKBROOK TERRACE, Ill., Jan. 12, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), and Ferrara Candy Company, Inc. ("Ferrara"), announced today that Perrigo's Nutritionals division has signed a supply agreement with Ferrara to manufacture store brand gummy v
Read more →PRGOPerrigo Launches The Generic Version Of Clobex® (Clobetasol Propionate) Spray, 0.05%
DUBLIN, Jan. 12, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex® Spray, 0.05%. Perrigo was the first generic filer against this product and it is entitled to 180
Read more →PRGOPerrigo Company To Present At The 33rd Annual J.P. Morgan Healthcare Conference
DUBLIN, Jan. 6, 2015 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at the Westin St. Francis Hotel in San
Read more →PRGOPerrigo Company plc Announces The Closing Of Its Registered Public Offering Of Senior Notes
DUBLIN, Dec. 2, 2014 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of the previously announced registered public offering by Perrigo Finance plc, a public lim
Read more →PRGOPerrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares
DUBLIN, Nov. 26, 2014 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of Perrigo's previously announced registered public offering relating to the sale of 6,809
Read more →PRGOPerrigo Company plc Announces Proposed Public Offering Of Senior Notes Of Its Finance Subsidiary, Perrigo Finance plc
DUBLIN, Nov. 24, 2014 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that Perrigo Finance plc, a finance subsidiary of Perrigo incorporated under the laws of Ireland (the
Read more →PRGOPerrigo Company plc Announces The Pricing Of Senior Notes Offering By Its Finance Subsidiary, Perrigo Finance plc
DUBLIN, Nov. 24, 2014 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the pricing of the registered public offering by Perrigo Finance plc, a public limited company incorpo
Read more →PRGOPerrigo Announces The Launch Of A Generic Version Of Astellas
DUBLIN, Nov. 24, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic® Ointment 0.1% and 0.03%. Shipments to our pharmacy customers have commenced. Protopic® Ointm
Read more →PRGOPerrigo Confirms First to File Patent Challenge for Generic Version of Aveed® (Testosterone Undecanoate) Injection
DUBLIN, Nov. 24, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for testosterone undecanoate injection and that it has notified the owner of the Ref
Read more →PRGOPerrigo Company plc Announces Underwriters
DUBLIN, Nov. 24, 2014 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that the underwriters for Perrigo's previously announced public equity offering of 5,921,053 ordinary
Read more →PRGOPerrigo Company plc Announces Proposed Public Offering Of Ordinary Shares
DUBLIN, Nov. 20, 2014 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that it is commencing a registered public offering of $900,000,000 of its ordinary shares, subject to
Read more →PRGOPerrigo Company PLC Reports Record First Quarter Revenue, Adjusted Net Income And Adjusted Margins
DUBLIN, Nov. 6, 2014 /PRNewswire/ -- Fiscal first quarter net sales increased to a first quarter record of $952 million. Fiscal first quarter adjusted net income increased 30% to a first quarter record of $188 million, with reported GAAP net income of $96 million. Adjusted and
Read more →PRGOPerrigo Reinitiates Shipments Of Guaifenesin Extended-Release 600mg Tablets, The Store Brand Equivalent To Mucinex® 600mg Extended-Release Tablets
DUBLIN, Nov. 6, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under
Read more →PRGOPerrigo Company plc To Acquire Omega Pharma NV For EUR 3.6 Billion Creating A Top Five Global OTC Company
DUBLIN, Nov. 6, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced tha
Read more →PRGOPerrigo Company plc To Release First Quarter Fiscal Year 2015 Results On November 6, 2014
DUBLIN, Oct. 23, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal year 2015 on Thursday, November 6, 2014 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at
Read more →PRGOPerrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043
DUBLIN, Oct. 2, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a public limited company incorporated under the laws of Ireland (the "Company"), today announced the expiration of its offer to exchange (the "Exchange Offer") up to $500,000,000 of its new 1.30% Senior
Read more →PRGOPerrigo Company plc Announces Extension of Exchange Offer for Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043
DUBLIN, Oct. 1, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE), a public limited company incorporated under the laws of Ireland (the "Company"), today announced the extension of its offer to exchange (the "Exchange Offer") up to $500,000,000 of its new 1.30% Senior N
Read more →PRGOPerrigo Enters New Therapeutic Category With The Acquisition Of Women
DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has signed a definitive agreement to acquire a portfolio of women's healthcare products from Lumara Health, Inc., a privately-held, Chesterfield, Missouri-based specialty pharmac
Read more →PRGOPerrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals
DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development com
Read more →PRGOPerrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043
DUBLIN, Sept. 2, 2014 /PRNewswire/ -- Perrigo Company plc, a public limited company incorporated under the laws of Ireland (the "Company"), today announced that it is offering to exchange (the "Exchange Offer") up to $500,000,000 of its new 1.30% Senior Notes due 2016 (the "2016
Read more →PRGOPerrigo Company plc Reports Record Fourth Quarter And Fiscal Year Revenue, Adjusted Operating Income And Adjusted Margins. Conference call scheduled for 10 a.m. ET today.
DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Fiscal fourth quarter net sales increased 18% year-over-year to a record $1.14 billion. Fiscal fourth quarter adjusted net income increased 58% to $234 million, or $1.74 per diluted share; GAAP net income of $132 million, or $0.98 per dilut
Read more →PRGOPerrigo Company plc To Release Fourth Quarter And Fiscal Year 2014 Results On August 14, 2014
DUBLIN, July 31, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its fourth quarter and fiscal year 2014 on Thursday, August 14, 2014 at approximately 8:00 a.m. (ET). The Company will conduct a conference call
Read more →PRGOPerrigo Company plc To Present At Jefferies 2014 Global Healthcare Conference
DUBLIN, May 30, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 10AM ET at the Grand Hyatt Hotel in New Y
Read more →PRGOPerrigo Company plc Announces FDA Approval Of Generic Version Of Astepro® Nasal Spray
DUBLIN, May 12, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO;TASE) announced that it has received final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal spray (0.15%). The ANDA invo
Read more →PRGOPerrigo Company plc To Release Third Quarter Fiscal Year 2014 Results On May 7, 2014
DUBLIN, April 23, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its third quarter fiscal year 2014 on Wednesday, May 7, 2014 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:
Read more →PRGOPerrigo Announces Launch Of Authorized Generic Version Of Taclonex® Ointment (Calcipotriene 0.005% / Betamethasone Dipropionate 0.064%)
DUBLIN, April 1, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has initiated market launch and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex® Ointment (calcipotriene 0.005% / betamethasone dipropionate
Read more →PRGOPerrigo Partners With Division Of Golden State Foods To Manufacture Store Brand Versions Of Ensure® Adult Nutritional Drinks
DUBLIN, March 26, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Nutritionals segment is partnering with KanPak LLC to manufacture store brand adult nutritional drinks comparable to Ensure® products. KanPak is a leading supplier of beverages
Read more →PRGOPerrigo Company plc Announces Acquisition Of OTC Products In Australia
DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO;TASE) announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc. for $51 million in cash. The products are primarily sold through the mass retai
Read more →PRGOPerrigo Company plc Announces The Transfer Of Development Asset ELND005 To Transition Therapeutics Inc.
DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) announced today that it entered into a series of agreements with existing collaboration partner, Transition Therapeutics Inc. (Nasdaq: TTHI), to progress the clinical development of ELND005 (Scyllo-inosi
Read more →PRGOPerrigo Company plc To Present At Upcoming Healthcare Conference
DUBLIN, Feb. 19, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 8am at the New York Palace H
Read more →PRGOPerrigo Company plc Reports Record Revenue, Adjusted Earnings and Margins
DUBLIN, Feb. 6, 2014 /PRNewswire/ -- Fiscal second quarter net sales increased 11% year-over-year to a record $979 million. Fiscal second quarter adjusted net income increased 45% to a record $185 million, or $1.87 per diluted share. Fiscal second quarter GAAP net loss of $86
Read more →PRGOPerrigo Company plc to Release Second Quarter Fiscal Year 2014 Results on February 6, 2014
DUBLIN, Jan. 23, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter fiscal year 2014 on Thursday, February 6, 2014 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at
Read more →PRGOPerrigo Company plc Names Board of Directors
DUBLIN, Dec. 18, 2013 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) today announced the appointment of its Board of Directors, effective until Perrigo Company's annual general meeting scheduled for November 2014. The appointment of the Perrigo Company plc Board follows the com
Read more →PRGOPerrigo Company to Join the NASDAQ-100 Index Beginning December 6, 2011
NEW YORK, Dec. 1, 2011 (GLOBE NEWSWIRE) -- Perrigo Company (Nasdaq:PRGO) will become a component of the NASDAQ-100 Index (Nasdaq:NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq:NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq:NDXX) prior to market open on Tuesday, December
Read more →PRGOPerrigo Company (PRGO) Chief Executive Officer to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, Sept. 25, 2009 (GLOBE NEWSWIRE) -- Joseph C. Papa, CEO of Perrigo Company [PRGO], will preside over the NASDAQ closing bell. NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio Monday, September 28, 2009 at 3:45 p.m. to 4:00 p.m. ET Daniel B. Wi
Read more →PRGOPerrigo Company to Present At the Deutsche Bank 34th Annual Health Care Conference
Perrigo Company announced that its Chairman and CEO, Joseph C. Papa, will present at the Deutsche Bank 34th Annual Health Care Conference on May 18. The event will take place at the InterContinental Hotel in Boston. Perrigo is recognized as a leading global healthcare supplier, specializing in OTC and prescription pharmaceuticals.
Read more →PRGOPerrigo Company to Present At the Bank of America and Merrill Lynch 2009 Healthcare Conference
Perrigo Company announced that its Chairman and CEO, Joseph C. Papa, will present at the Bank of America and Merrill Lynch 2009 Healthcare Conference. The presentation is scheduled for May 13 at 10:40 a.m. ET in New York. Perrigo is recognized as a leading global healthcare supplier.
Read more →PRGOPerrigo Company (PRGO) Chairman and Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, July 24, 2008 (PRIME NEWSWIRE) -- Joseph C. Papa, Chairman and Chief Executive Officer of Perrigo Company (PRGO), will preside over the Opening Bell. NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio Friday, July 25, 2008 at 9:30 a.m. EDT ajsh
Read more →PRGOPerrigo Company (PRGO) President and Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell
ADVISORY, Dec. 15, 2006 (PRIME NEWSWIRE) -- Joseph C. Papa, President and Chief Executive Officer of Perrigo Company (PRGO) will preside over the opening bell NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio Monday, December 18, 2006 at 9:30 a.m. ET Ar
Read more →Competitive Position
How PRGO ranks across every disease it competes inCompetitive Position is a premium feature
See how PRGO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial